



- (51) **International Patent Classification:**
G01N 33/566 (2006.01) *C12P 19/36* (2006.01)
- (21) **International Application Number:**
PCT/US2014/065058
- (22) **International Filing Date:**
11 November 2014 (11.11.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/902,680 11 November 2013 (11.11.2013) US
61/912,625 6 December 2013 (06.12.2013) US
61/993,328 15 May 2014 (15.05.2014) US
- (71) **Applicants:** **BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM** [US/US]; 201 West 7th Street, Austin, Texas 78701 (US). **UNIVERSITY OF IOWA RESEARCH FOUNDATION** [US/US]; 112 N Capitol Street, 6 Gilmore Hall, Iowa City, Iowa 52242-5500 (US).
- (72) **Inventors:** **MCKNIGHT, Steven L.**; 8513 Swananoah Road, Dallas, Texas 75209 (US). **READY, Joseph M.**; 3157 Riverside Drive, Carrollton, Texas 75007 (US). **PIEPER, Andrew A.**; 482 Butternut Lane, Iowa City, Iowa 52246 (US). **WANG, Gelin**; 4432 Waskom Drive,

Plano, Texas 75024 (US). **HAN, Ting**; 5205 Fleetwood Oak Avenue, Apt. B, Dallas, Texas 75235 (US).

- (74) **Agents:** **DYKEMAN, David J.** et al.; Greenberg Traurig, One International Place, Boston, Massachusetts 02110 (US).


- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

- (54) **Title:** NEUROPROTECTIVE CHEMICALS AND METHODS FOR IDENTIFYING AND USING SAME

Figure 1



- (57) **Abstract:** Provided herein is a method for identifying a compound having neuroprotective activity, including: providing a population of cells treated with a test compound for a first period of time; subjecting the population of cells to doxorubicin for a second period of time; and determining survival rate of the population of cells; wherein an increase in the survival rate compared to a control that is not treated with the test compound is indicative of neuroprotective activity of the test compound. Compounds identified therefrom are also provided. These compounds can be used to treat various diseases, disorders, or conditions associated with neuronal cell death.

Published:

— *with international search report (Art. 21(3))*

Neuroprotective Chemicals and Methods for Identifying and Using Same

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of and priority to U.S. Provisional Patent Application Nos.

5 61/902,680 filed November 11, 2013; 61/912,625 filed December 6, 2013 and 61/993,328 filed May 15, 2014, the entire disclosures of all of which are hereby incorporated by reference.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

10 This invention was made with government support under Grant No. 5-R01-MH087986 awarded by the National Institute of Mental Health; the Government has certain rights in the invention.

FIELD

15 This disclosure relates to methods for identifying and using neuroprotective compounds capable of reducing neuronal cell death.

BACKGROUND

It is now accepted that the adult vertebrate brain fosters the birth and functional incorporation of newly formed neurons (Goldman and Nottebohm, Proc Natl Acad Sci USA 1983, 80: 2390-2394; Paton and Nottebohm, Science 1984, 225, 1046-1048; Burd and Nottebohm, J Comp Neurol 1985, 240:143-152). However, it was long thought that no new neurons could be added to the adult mammalian brain. This dogma was challenged in the 1960's when autoradiographic evidence of new neuron formation in the hippocampal dentate gyrus, olfactory bulb, and cerebral cortex of the adult rat was presented (Altman, J. Science 1962, 135, 1127-1128; Altman, J. J Comp Neurol 1966, 128:431-474; Altman, Anat Rec 1963, 145:573-591; Altman and Das, J. Comp. Neurol. 1965, 124, 319-335; Altman and Das, J Comp Neurol 1966, 126:337-390). It is now accepted that within all mammalian species, including humans (Eriksson et al., Nat. Med. 1998, 4(11), 1313-1317), there are two major reservoirs of neuronal stem cells, one located in the subgranular zone (SGZ) of the hippocampal dentate gyrus and another in the subventricular zone (SVZ) (Gross, Natl. Rev. 2000, 1, 67-72). Neural stem cells in the SVZ facilitate formation of new neurons that migrate rostrally to

populate the olfactory bulb, while neural stem cells in the SGZ produce neurons that integrate locally in the granular layer of the dentate gyrus, a region of the hippocampus that exhibits lifelong structural and functional plasticity.

5 The process of new neuron formation in the adult mouse brain can be influenced by environmental, chemical and genetic variables. As demonstrated by Gage and colleagues, neurogenesis in the adult mouse brain is enhanced when animals are exposed to an enriched environment (Kempermann et al., *Nature* 1997, 386, 493–495) or able to exercise voluntarily (van Praag et al., *Nat. Neuro-sci.* 1999, 2, 266–270). More recently, anti-depressant drugs have been shown to enhance levels of adult
10 neurogenesis in animals, including humans (Schmidt et al., *Behav Pharmacol.* 2007 Sep;18(5-6):391-418; Boldrini et al., *Neuropsychopharmacology* 2009, 34, 2376–2389). Among many genes reported to impact adult neurogenesis is the gene encoding neuronal PAS domain protein 3 (NPAS3), a central nervous system (CNS)-specific transcription factor that has been associated with schizophrenia and bipolar disorder (Kamnasaran et al., *J. Med. Genet.* 2003, 40, 325–332; Pickard et al., *Am. J. Med. Genet. B. Neuropsychiatr. Genet.* 2005, 136B, 26–32; Pickard et al., *Ann. Med.* 2006, 38, 439–448; Pickard et al., *Mol. Psychiatry* 2009, 14, 874–884; Lavedan et al., *Pharmacogenomics* 2008, 9: 289–301). Animals missing both copies of the NPAS3 gene suffer a profound loss of adult hippocampal neurogenesis coupled with significant behavioral deficits (Pieper et al., *Proc. Natl. Acad. Sci. USA* 2005, 102, 14052–14057). Knowing that impaired post-natal neurogenesis elicits
15 unfavorable phenotypic deficits, it is predicted that pro-neurogenic chemical compounds should exhibit favorable therapeutic benefits for a variety of neuropsychiatric and neurodegenerative diseases.

25 Neurodegenerative diseases currently affect millions of people worldwide, and the incidence of disease is rapidly increasing as the aging population expands. The magnitude and trend of this problem places a growing human and financial strain on healthcare systems, which is exacerbated by the absence of effective treatments for many of the most common afflictions.

Neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), traumatic brain injury (PDI) and normal age-related cognitive decline, feature, by definition,

neuronal cell death. Thus, there remains a great need for small molecules that could prevent the death of neurons in a variety of *in vivo* contexts. Such neuroprotective agents could possess general utility for treating disorders associated with neuron cell death.

5 SUMMARY

This invention relates generally to methods for identifying compounds that promote survival of existing neurons, reduce neuronal cell death, protect neurons from axonal degeneration, and/or promote neurogenesis (e.g., hippocampal neurogenesis) in the mammalian brain. For the purpose of simplicity these compounds are referred to as being neuroprotective. In certain embodiments, 10 the compounds promote survival and integrity of neurons in the post-natal mammalian brain. In certain embodiments, the compounds are neuroprotective, that is, they promote the survival, health, integrity, growth, development and/or function of neurons, and/or protect neurons from cell death, apoptosis and/or degeneration, particularly CNS, brain, cerebral, and hippocampal neurons. In certain embodiments, the compounds stimulate post-natal hippocampal neurogenesis, 15 reduce neuronal cell death, and/or protect neurons from axonal degeneration, which while not wishing to be bound by theory, is believed to represent a therapeutic target useful for treating a variety of diseases. Also included are compounds identified by such methods, and use of the compounds for the treatment of various diseases.

20 Provided herein, in one aspect, is a method for identifying a compound having neuroprotective activity. The method includes: incubating a test compound with a nicotinamide phosphoribosyltransferase (NAMPT); and measuring an activity of the NAMPT; wherein an increase in the activity of the NAMPT compared to a control that is not incubated with the test compound is indicative of neuroprotective activity of the test compound.

25 In some embodiments, in the incubating step, the NAMPT is recombinantly produced and optionally further purified. The NAMPT can be present at about 0.1 to about 10 μM , about 0.5 to about 5 μM , or about 1 μM . In certain embodiments, the test compound can be additionally incubated with nicotinamide, phosphoribosylpyrophosphate, alcohol dehydrogenase, nicotinamide

mononucleotide adenylyl-transferase, and an alcohol (e.g., ethanol). In embodiments, the measuring step includes determining an amount of nicotinamide adenine dinucleotide reduced form (NADH), which can optionally be measured by ultra violet light. In one example, the amount of NADH is measured by optical density 340 nm. In some embodiments, an increase in the amount of NADH is indicative of increased NAMPT activity. In embodiments, the test compound having said neuroprotective activity can be further determined to bind and/or activate the NAMPT. In some examples, the method further includes determining that the test compound having said neuroprotective activity binds and/or activates the NAMPT, e.g., by mass spec and/or gel electrophoresis.

A further aspect relates to another method for identifying a compound having neuroprotective activity. The method includes: exposing a population of cells to a test compound and a DNA-damaging agent; and determining survival rate of the population of cells; wherein an increase in the survival rate compared to a control that is not treated with the test compound is indicative of neuroprotective activity of the test compound.

In some embodiments, the exposing step comprises incubating the population of cells with the test compound and the DNA-damaging agent. In some alternative embodiments, the exposing step comprises incubating the population of cells with the test compound first, followed by the DNA-damaging agent. In yet other embodiments, the exposing step comprises incubating the population of cells with the DNA-damaging agent first, followed by the test compound. The DNA-damaging agent may activate poly-ADP-ribose polymerase (PARP), and/or lead to decline in nicotinamide adenine dinucleotide (NAD) level. In certain embodiments, the DNA-damaging agent is an anthracycline. The anthracycline can be one or more of daunorubicin, doxorubicin, epirubicin, idarubicin, valrubicin and/or mitoxantrone. In one example, the anthracycline is doxorubicin. The DNA-damaging agent (e.g., doxorubicin) can be provided at about 0.01-20 μ M, or about 0.05-10 μ M, or about 0.1-1.5 μ M, or about 0.5 μ M. The test compound can be provided at about 1-20 μ M, or about 2-10 μ M or about 5 μ M. The test compound is a small molecule. In some embodiments, the cells are mammalian cells. In some embodiments, the test compound having said neuroprotective activity can be determined

to protect the cells from toxicity mediated by the DNA-damaging agent, and/or reduce apoptosis induced by the DNA-damaging agent. In certain embodiments, the test compound having said neuroprotective activity can be determined to not protect the cells from toxicity induced by a toxin selected from the group consisting of bortezomib, staurosporine, taxol, brefeldin, cytochalasin D, TNF α and TRAIL.

The DNA-damaging agent based method, in some embodiments, further comprises incubating the test compound with nicotinamide phosphoribosyltransferase (NAMPT) and measuring an activity of the NAMPT, wherein an increase in the activity of the NAMPT additionally confirms the neuroprotective activity of the test compound. In certain embodiments, the test compound having said neuroprotective activity is determined to increase nicotinamide adenine dinucleotide (NAD) level, and/or enhance intracellular production of the NAD by increasing the activity of the NAMPT. In some embodiments, the test compound having said neuroprotective activity is determined to bind and/or activate the NAMPT. In some examples, the method further includes determining that the test compound having said neuroprotective activity binds and/or activates the NAMPT, e.g., by mass spec and/or gel electrophoresis.

In another aspect, a compound having neuroprotective activity, identified by the methods described herein is provided. In some embodiments, the compound can have a $\Delta(\text{Sinf-S0})/\text{AC50}$ value greater than about 0, or greater than about 1, or greater than about 2, or greater than about 3, or greater than about 4, or greater than about 5, or greater than about 10, or greater than about 20, or greater than about 30, or greater than about 40, or greater than about 50, or greater than about 60, or greater than about 70, or greater than about 80, or greater than about 90, or greater than about 100. $\Delta(\text{Sinf-S0})/\text{AC50}$ represents change in protection activity compared to vehicle control. Protection activity is expressed by $(\text{Sinf-S0})/\text{AC50}$ in the twelve-point dose response curve (DRC) corresponding to each compound, wherein both efficacy and potency of compounds were considered. Sinf represents the expected maximal protection. S0 is the baseline. AC50 is the concentration of a compound where 50% of its maximal protection effect was observed.

In certain embodiments, the compounds can bind and/or activate nicotinamide phosphoribosyltransferase (NAMPT). The compounds may enhance an activity of NAMPT. The compounds may also enhance NAD levels compared to the control. In some embodiments, the compounds enhance intracellular production of NAD by agonizing or increasing an activity of NAMPT.

Also provided herein is a pharmaceutical composition comprising one or more of the compounds identified by the methods described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

In a further aspect, a method for the treatment of a disease, disorder, or condition associated with unwanted neuronal cell death is provided. The method includes administering an effective amount of one or more of the compounds identified by the methods described herein, or a pharmaceutically acceptable salt thereof, to a patient in need thereof. In some embodiments, the compound or salt enhances NAD levels.

In yet another aspect, a method for the treatment of a disease, disorder, or condition associated with unwanted neuronal cell death is provided, which includes administering an effective amount of one or more of the compounds described herein, or a pharmaceutically acceptable salt thereof, to a patient in need thereof, wherein the compound or salt binds NAMPT. In some embodiments, the compound or salt enhances NAD levels.

In yet another aspect, a method for the treatment of a disease, disorder, or condition associated with unwanted neuronal cell death is provided, which includes administering an effective amount of one or more of the compounds described herein, or a pharmaceutically acceptable salt thereof, to a patient in need thereof, wherein the compound or salt activates NAMPT. In some embodiments, the compound or salt enhances NAD levels.

In some embodiments, the disease, disorder, or condition is selected from: DNA-damaging agent

(e.g., anthracycline) mediated cardiotoxicity, schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury and/or a visual symptom associated therewith, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, cognitive decline and/or general frailty associated with normal aging and/or chemotherapy, chemotherapy induced neuropathy, concussive injury, crush injury, peripheral neuropathy, diabetic neuropathy, post-traumatic headache, multiple sclerosis, retinal degeneration and dystrophy (such as Leber congenital amaurosis, retinitis pigmentosa, cone-rod dystrophy, microphthalmia, anophthalmia, myopia, and hyperopia), spinal cord injury, traumatic spinal cord injury, peripheral nerve injury (such as peripheral nerve crush injury, neonatal brachial plexus palsy, and traumatic facial nerve palsy), retinal neuronal death related diseases (such as glaucoma and age related macular degeneration, diabetic retinopathy, retinal blood vessel occlusions, retinal medication toxicity (such as what amino glycosides or plaquenil can cause), retinal trauma (e.g., post-surgical), retinal infections, choroidal dystrophies, retinal pigmentary retinopathies, inflammatory and cancer mediated auto immune diseases that result in retinal neuronal cell death), Autism, Stargardt disease, Kearns-Sayre syndrome, Pure neurosensory deafness, Hereditary hearing loss with retinal diseases, Hereditary hearing loss with system atrophies of the nervous system, Progressive spinal muscular atrophy, Progressive bulbar palsy, Primary lateral sclerosis, Hereditary forms of progressive muscular atrophy and spastic paraplegia, Frontotemporal dementia, Dementia with Lewy bodies, Corticobasal degeneration, Progressive supranuclear palsy, Prion disorders causing neurodegeneration, Multiple system atrophy (olivopontocerebellar atrophy), Hereditary spastic paraparesis, Friedreich ataxia, Non-Friedreich ataxia, Spinocerebellar atrophies, Amyloidoses, Metabolic-related (e.g., Diabetes) neurodegenerative disorders, Toxin-related neurodegenerative disorders, Multiple sclerosis, Charcot Marie Tooth, Diabetic neuropathy, Metabolic neuropathies, Endocrine neuropathies, Orthostatic hypotension, Creutzfeldt-Jacob Disease, Primary progressive aphasia, Frontotemporal Lobar Degeneration, Cortical blindness, Shy-Drager Syndrome (Multiple, System Atrophy with Orthostatic Hypotension), Diffuse cerebral cortical atrophy of non-Alzheimer

type, Lewy-body dementia, Pick disease (lobar atrophy), Thalamic degeneration, Mesolimbocortical dementia of non-Alzheimer type, Nonhuntingtonian types of chorea and dementia, Cortical-striatal-spinal degeneration, Dementia-Parkinson-amyotrophic lateral sclerosis complex, Cerebrocerebellar degeneration, Cortico-basal ganglionic degeneration, Familial dementia with spastic paraparesis or myoclonus, and Tourette syndrome.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1B. Protection of cultured U2OS cells from doxorubicin-mediated toxicity by active derivatives of P7C3. (FIG. 1A) U2OS cells were treated with 5 μ M P7C3-A20 for 2 h prior to incubation with the indicated concentrations of doxorubicin for 72h. (FIG. 1B) Comparison of the P7C3-S243 enantiomers in protection of cells from doxorubicin revealed that (-)-P7C3-S243 was more active than (+)-P7C3-S243, consistent with their respective neuroprotective activities in vivo (see text). In all cell survival graphs, data are expressed as mean $\pm$ standard deviation (SD) of experimental duplicates.

FIGS. 2A-2D. Identification of the P7C3 binding protein p70 using the P7C3-S326 photo-crosslinking probe. (FIG. 2A) Chemical structure of P7C3-S326. (FIG. 2B) Full gel image of photo-crosslinking in H2122 cells with P7C3-S326 followed by click chemistry with Alexa 532 dye. The active analog P7C3-A20 competed away the UV-dependent binding of p70 to P7C3-S326. (FIG. 2C) Formulas used for calculating doxorubicin toxicity (dox:tox) protection activity. Protection activity is expressed by (Sinf-S0)/AC50 in the twelve-point dose response curve (DRC) corresponding to each compound, wherein both efficacy and potency of compounds were considered. Sinf represents the expected maximal protection. S0 is the baseline. AC50 is the concentration of a compound where 50% of its maximal protection effect was observed. (FIG. 2D) Scatter plot of 168 derivatives of P7C3 revealed a significant correlation between protective activity of P7C3 analogs from doxorubicin-mediated toxicity and their ability to compete for photo-crosslinking of P7C3-S326 to p70. In the photo-crosslinking assays, the p70 band intensity was quantified by Image J, and compared the sample of P7C3-S326 alone with that of P7C3-S326 plus competitor. Pearson correlation coefficient (r) and two tailed P value were determined by GraphPad Prism 6 and Spearman Rank Correlation (v1.0.1)

software.

FIGS. 3A-2D. Identification of p70 and p55 targets of P7C3 by two-dimensional gel electrophoresis and mass spectrometry. Lysates from cells exposed to 0.3 μ M P7C3-S326 were CLICKed with a green dye, Alexa 532, and those from cells co-exposed to 0.3 μ M P7C3-S326 and 5 μ M of the active competitor P7C3-A20 were CLICKed with a red dye Cy5. CLICK reacted lysates were combined, subjected to two-dimensional gel electrophoresis, and scanned in the green channel (FIG. 3A) and the red channel (FIG. 3B). Images from both channels were merged to reveal green-only spots (FIG. 3C). After spot picking, total proteins were visualized by Sypro Ruby staining (FIG. 3D). White circles in (FIG. 3D) indicate spots excised for shotgun mass spectrometry analysis.

FIGS. 4A-4B. Conversion of p70 into p55 in the presence of urea. (FIG. 4A) CLICK reacted lysates from H2122 cells treated with P7C3-S326 were separated on a standard 8% SDS-PAGE gel (left panel) or one supplemented with 7M urea (right panel), and visualized on a Typhoon scanner. Asterisk indicates the crosslinked protein that migrates as 70KDa in a standard SDS-PAGE gel and 55KDa in the SDS-PAGE gel supplemented with 7M urea. (FIG. 4B) The same lysates were resolved on a horizontal urea gradient gel co-loaded with crosslinked p70 and the same 75kD and 50kD size standard proteins displayed in FIG. 4A. The horizontal urea gradient proceeds from zero denaturant on the left to 7M denaturant on the right.

FIGS. 5A-5C. Active variants of P7C3 compensate NAD exhaustion induced by doxorubicin. (FIG. 5A) U2OS cells were treated with the indicated concentration of P7C3-A20. Cells were harvested and NAD metabolites were measured by LC-MS/MS. Abundance of NAD was normalized relative to total metabolites (Experimental Procedures). The data are represented as the mean $\pm$ SD of experimental duplicates. (FIG. 5B) Active derivatives P7C3-A20 and P7C3-S243, but not inactive derivatives P7C3-S6, or P7C3-S117, facilitate replenishment of NAD levels in doxorubicin-treated cells. Cells were grown in 96-well plates and treated with the indicated concentrations of P7C3-A20, P7C3-S243, P7C3-S6 or P7C3-S117 together with 0.5 μ M doxorubicin for 45h. Cellular NAD abundance was determined by NAD/NADH Glo assay kit. (FIG. 5C) Scatter plots revealed a strong correlation

between dox:tox protective activities of 159 compounds and their relative abilities to replenish NAD levels. The activities in both assays are represented by (Sinf-S0)/AC50 in dose response curves of test compounds.

FIGS. 6A-6B. P7C3-A20 enhances the flux of nicotinamide through the salvage pathway. (FIG. 6A) Cells were pre-treated with 0.5 μ M doxorubicin for 48 hours, followed by 6 hours treatment with ¹⁴C-nicotinamide in the presence of the indicated amount of P7C3-A20. Metabolites were extracted and analyzed by thin layer chromatography. (FIG. 6B) Quantification of the relative intensities of NAD and NMN from the thin layer chromatogram.

FIGS. 7A-7C. Active variants of P7C3 enhance the activity of purified NAMPT enzyme. (FIG. 7A) P7C3-A20 was incubated at indicated concentrations in a reaction coupled with three enzymes; NAMPT, NMNAT, and ADH (Experimental Procedures). NAMPT activity was recorded for the indicated period of time at OD340nm by measuring NADH appearance, leading to the indicated concentration-time plot. Each assay was repeated three independent times with similar results. (FIG. 7B) Analysis of the activities of thirty P7C3 analogs was performed to assess their effects on NAMPT enzymatic activity. The reaction rate was calculated as the slope of the concentration-time curve. Relative reaction rate was normalized by the control reaction run prior to compound addition. Data represents the mean of experimental duplicates. Scatter graphs were plotted to compare the ability of compounds to activate NAMPT relative to their ability to compete away P7C3-S326 crosslinking (top scatter plot), ability to protect cells from doxorubicin-mediated toxicity (middle scatter plot), or ability to facilitate NAD restoration in doxorubicin-treated cells (bottom scatter plot). Significant correlations were observed from all three sets of data. (FIG. 7C) Comparison of P7C3-S243 enantiomers showed that (-)-P7C3-S243 was superior to (+)-P7C3-S243 in activating the purified NAMPT enzyme. Data are expressed as mean $\pm$ SD of duplicate independent assays.

FIG. 8. P7C3A20 protects U2OS cells from doxorubicin-mediated toxicity. U2OS cells were treated with 5 μ M P7C3-A20 for 2 h prior to incubation with the indicated concentrations of eight toxins for 72h.

FIGS. 9A-9B. P7C3A20 blocks apoptosis, but not DNA damage response induced by doxorubicin. (FIG. 9A) U2OS cells were treated with increasing concentrations of P7C3-A20 for 2 h prior to exposure to 0.5 μ M doxorubicin for another 2 h. Cells were harvested and subjected to western blotting with the DNA damage marker, γ -H2AX. Actin was served as loading control. (FIG. 9B) U2OS cells were treated with P7C3-A20 and doxorubicin for the indicated time. Caspase-3 activation was determined by western blotting. Caspase-3 cleavage was observed when treated with doxorubicin alone at 60h, but was prevented in the presence of P7C3-A20.

FIG. 10. Twelve-point dose response curves (DRC) of all tested compounds in doxorubicin toxicity protection assay. The cells were grown in 384-well plates and treated with 5 μ M-1.7nM (3-fold serial dilution) of various P7C3 derivatives together with 0.5 μ M doxorubicin for 72h. Cell viability was determined by Cell Titer Glo assay kit.

FIG. 11. Competition for photo-crosslinking of P7C3-S326 to p70 of all tested compounds. Lysates from crosslinked cells exposed to 0.3 μ M P7C3-S326 and 5 μ M of various P7C3 derivatives were CLICKed with Alexa 532 and visualized on SDS-PAGE.

FIG. 12. Five-point dose response curves (DRC) of all tested compounds in NAD rebound assay. Cells were grown in 384-well plates and treated with 5 μ M-62nM (3-fold serial dilution) of various P7C3 derivatives together with 0.5 μ M doxorubicin for 45h. Cellular NAD abundance was determined by NAD/NADH Glo assay kit.

DETAILED DESCRIPTION

A number of small molecules with *in vivo* neuroprotective properties have been previously identified and disclosed in US Patent No. 8,362,277; U.S. Publication No. 2011/0015217; U.S. Publication No. 2012/0022096 and U.S. Publication No. 2013/0040977; and U.S. Application No. 14/339,772 filed July 24, 2014, all of which are hereby incorporated herein by reference in their entirety, in particular the compounds disclosed in the Examples section. Additional compounds are

disclosed in U.S. Provisional Patent Application No. 61/902,680 filed November 11, 2013 and U.S. Provisional Patent Application No. 61/912,625 filed December 6, 2013, all of which are hereby incorporated herein by reference in their entirety, in particular the compounds disclosed in the Examples section.

5

It has now been surprisingly discovered that the *in vivo* neuroprotective properties of these compounds coincide or correlate with their protective activity against DNA-damaging agent-mediated cell toxicity. Unexpectedly, such protection is unique to DNA-damaging agent such as anthracyclines as these compounds do not protect cells from toxicity induced by other potent toxins
10 such as bortezomib, staurosporine, taxol, brefeldin, cytochalasin D, TNF α and TRAIL. As such, DNA-damaging agents can be used in a method to screen for or identify compounds having neuroprotective activity.

DNA-damaging agents are widely used in treatment of malignant conditions such as various cancer.
15 However, they are also known to induce cardiac toxicity, especially dose-dependent cardiomyopathy. As such, compounds identified to have protective activity against DNA-damaging agent (e.g., anthracycline) mediated toxicity can also be used to treat DNA-damaging agent (e.g., anthracycline) mediated cardiotoxicity. In some embodiments, such compounds can be administered along with, or subsequent to, DNA-damaging agent (e.g., anthracycline)
20 administration.

Another surprising finding is that the compounds bind to and/or activate nicotinamide phosphoribosyltransferase (NAMPT). The compounds may enhance an activity of NAMPT. The compounds may also enhance nicotinamide adenine dinucleotide (NAD) levels. In some
25 embodiments, the compounds enhance intracellular production of NAD by agonizing an activity of NAMPT. Thus, in addition to the neuroprotective activities that render these compounds useful in treating diseases or conditions associated with, for example, unwanted neuronal cell death and/or insufficient neurogenesis, they can also be used as potential treatments for generalized frailty typical of aged animals and humans, since NAD is an important coenzyme found in all living cells and

is involved in numerous redox reactions in metabolism.

Definitions

Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which the disclosure pertains. The Definitions section at paragraphs [1001]-[1031] of U.S. Publication No. 2013/0040977 is incorporated herein by reference. Specific terminology is defined below.

As used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

As used herein, the term "about" means within 20%, more preferably within 10% and most preferably within 5%.

The terms "neuroprotective" and "neuroprotective activity" refer to an activity in promoting the survival, health, integrity, growth, development and/or function of neurons, and/or protecting neurons from cell death, apoptosis and/or degeneration, and/or stimulating neurogenesis, particularly CNS, brain, cerebral, and hippocampal neurons.

The term "neurogenesis" refers to the process by which neurons are generated from neural stem cells and progenitor cells, which is responsible for populating the growing brain with neurons. While neurogenesis generally is most active during pre-natal development, in some embodiments the compounds disclosed herein can stimulate or promote post-natal neurogenesis such as hippocampal neurogenesis.

The terms "treating" and "treatment" as used herein refer to reduction in severity and/or frequency of symptoms, elimination of symptoms and/or underlying cause, and improvement or remediation of damage.

By "pharmaceutically acceptable" is meant a material that is not biologically or otherwise undesirable, i.e., the material may be incorporated into a pharmaceutical composition administered to a patient without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained. When the term

5 "pharmaceutically acceptable" is used to refer to a pharmaceutical carrier or excipient, it is implied that the carrier or excipient has met the required standards of toxicological and manufacturing testing and/or that it is included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug administration.

10 As used herein, the term "patient" or "individual" or "subject" refers to any person or mammalian subject for whom or which therapy is desired, and generally refers to the recipient of the therapy to be practiced according to the disclosure.

The term "substituent" refers to a group "substituted" on, e.g., an alkyl, haloalkyl, cycloalkyl, heterocyclyl, heterocycloalkenyl, cycloalkenyl, aryl, or heteroaryl group at any atom of that group, replacing one or more hydrogen atom therein. In one aspect, the substituent(s) on a group are independently any one single, or any combination of two or more of the permissible atoms or groups of atoms delineated for that substituent. In another aspect, a substituent may itself be substituted with any one of the above substituents. Further, as used herein, the phrase "optionally

15 substituted" means unsubstituted (e.g., substituted with an H) or substituted. It is understood that substitution at a given atom is limited by valency. Common substituents include halo, straight chain or branched chain alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkylsulfonyl, nitro, cyano, -COOR, -C(O)NRR', -OR, -SR, -NRR', and oxo, such as mono- or di- or tri-substitutions with moieties such as trifluoromethoxy, chlorine, bromine, fluorine, methyl, methoxy, pyridyl, furyl,

20 triazyl, piperazinyl, pyrazoyl, imidazoyl, and the like, each optionally containing one or more heteroatoms such as halo, N, O, S, and P. R and R' are independently hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl. Unless otherwise noted, all groups described herein optionally contain one or more common substituents, to the extent permitted by valency.

Screening Methods

Aspects of the invention relate to screening methods for identifying a compound having neuroprotective activity. These methods can be used in high-throughput screens of many compounds in parallel, e.g., at least 10 compounds, at least 50 compounds, at least 100 compounds, at least 500 compounds, at least 1000 compounds, at least 10,000 compounds, or more or less compounds.

In one aspect, a method for identifying a compound having neuroprotective activity is based on the surprising discovery that certain compounds (e.g., the P7C3 class of compounds) are capable of activating nicotinamide phosphoribosyltransferase (NAMPT). The method can include: incubating a test compound with a NAMPT; and measuring an activity of the NAMPT; wherein an increase in the activity of the NAMPT compared to a control that is not incubated with the test compound is indicative of neuroprotective activity of the test compound.

In some embodiments, the test compound can be provided at any suitable amount or concentration, e.g., about 0.1-20 μ M, or about 0.3-5 μ M, about 1 μ M or about 3 μ M, or any other suitable concentration one of ordinary skill can determine through routine experimentation depending on the specific compound. The test compound can be any compound or agent of interest. The test compound can be a small molecule (e.g., having a molecular weight less than 1000 Da). The test compound can be from a library. In one example, the test compound may be selected from the compounds listed in Table 1. The test compound can also be those disclosed in US Patent No. 8,362,277; U.S. Publication No. 2011/0015217; U.S. Publication No. 2012/0022096 and U.S. Publication No. 2013/0040977; U.S. Application No. 14/339,772 filed July 24, 2014; U.S. Provisional Patent Application No. 61/902,680 filed November 11, 2013 and U.S. Provisional Patent Application No. 61/912,625 filed December 6, 2013, all of which are hereby incorporated herein by reference in their entirety, in particular the compounds disclosed in the Examples section.

In some embodiments, the NAMPT can be recombinantly produced and optionally further purified.

The NAMPT can be from a mammalian source such as human. Purified NAMPT is also commercially available. The NAMPT is present at about 0.1 to about 10 μM , about 0.5 to about 5 μM , or about 1 μM in the reaction mixture.

- 5 NAMPT activity can be measured by any suitable methods such as known immunometric, fluorometric and colorimetric assays (e.g., the CycLex® NAMPT Colorimetric Assay Kit by MBL International, and the assay described in Zhang et al., Anal. Biochem. 2011; 412(1):18-25 which is incorporated herein by reference in its entirety). In one example, NAMPT activity is measured by a coupled assay where the reaction mixture can further include nicotinamide,
- 10 phosphoribosylpyrophosphate, alcohol dehydrogenase, nicotinamide mononucleotide adenylyl-transferase (NMNAT), and an alcohol. NAMPT can convert nicotinamide to nicotinamide mononucleotide (NMN), which is then converted to NAD by NMNAT. In turn, NAD is reduced to the reduced form, NADH, by alcohol dehydrogenase, using alcohol (e.g., ethanol) as a substrate. The amount of NADH can be monitored by ultra violet light (e.g., optical density (OD) 340 nm), which
- 15 reflects the activity of NAMPT. That is, the higher the amount of NADH, the higher the activity of NAMPT.

- In some embodiments, the test compound having said neuroprotective activity can be further determined to bind and/or activate the NAMPT. Determining the test compound having said
- 20 neuroprotective activity binds and/or activates the NAMPT can be done by any suitable methods such as mass spec and/or gel electrophoresis.

- In a further aspect, another method for identifying a compound having neuroprotective activity is
- 25 based on the surprising finding that certain compounds (e.g., the P7C3 class of compounds) are capable of protecting cells from the toxicity induced by DNA-damaging agents. The method can include: exposing a population of cells to a test compound and a DNA-damaging agent; and determining survival rate of the population of cells; wherein an increase in the survival rate compared to a control that is not treated with the test compound is indicative of neuroprotective

activity of the test compound.

In some embodiments, the exposing step includes incubating the population of cells with the test compound and the DNA-damaging agent at the same time (e.g., in the same reaction mixture for the same amount of time). Alternatively, the population of cells can be incubated with the test compound first (e.g., for a first period of time such as 0.5-5 hours, or about 1-3 hours, or about 2 hours, or any other suitable length one of ordinary skill can determine through routine experimentation depending on the specific cells or compound), followed by the DNA-damaging agent (e.g., for a second period of time such as about 5-200 hours, or about 10-100 hours, or about 72 hours, or any other suitable length one of ordinary skill can determine through routine experimentation depending on the specific cells or the DNA-damaging agent). In yet another embodiment, the population of cells are incubated with the DNA-damaging agent first (e.g., for the second period of time), followed by the test compound (e.g., for the first period of time).

In certain embodiments, the DNA-damaging agent can activate poly-ADP-ribose polymerase (PARP). PARP uses NAD as the donor for poly-ADP-ribose synthesis and hence lowers cellular levels of NAD. Introduction of the compounds disclosed herein (e.g., the P7C3 class), by increasing or replenishing NAD levels, thus can protect the cells from toxicity induced by the DNA-damaging agent, increase their general health, and in some embodiments extend the life span of the cells.

In some embodiments, the DNA-damaging agent can be an anthracycline. Anthracycline is a class of drugs used in cancer chemotherapy. Examples include daunorubicin, doxorubicin, epirubicin, idarubicin, valrubicin and/or mitoxantrone. Anthracyclines have several mechanisms of action, including inhibition of DNA and RNA synthesis by intercalating between base pairs of the DNA/RNA strand, thus preventing the replication of rapidly growing cancer cells; inhibition of topoisomerase II enzyme, preventing the relaxing of supercoiled DNA and thus blocking DNA transcription and replication; iron-mediated generation of free oxygen radicals that damage the DNA, proteins and cell membranes; and induction of histone eviction from chromatin that deregulates DNA damage response, epigenome and transcriptome. These all lead to toxicity to the cells, eventually cell death.

The compounds disclosed herein (e.g., the P7C3 class) can mitigate and reverse the toxicity and/or cell death induced by anthracyclines. In one example, doxorubicin can be used as the DNA-damaging agent in the screen.

- 5 It has been surprisingly found that compounds having neuroprotective activity uniquely protects the cells from DNA-damaging agent (e.g., anthracycline) mediated toxicity, while failing to protect cells from toxicity induced by other powerful toxins such as bortezomib, staurosporine, taxol, brefeldin, cytochalasin D, TNF α and TRAIL. While without wishing to be bound by theory, it is hypothesized that because DNA-damaging agent (e.g., anthracycline) activates PARP which lowers cellular levels
10 of NAD, neuroprotective compounds can increase or replenish NAD levels, thereby protecting the cells from DNA-damaging agent (e.g., anthracycline) mediated toxicity, increasing the general health of the cells, and in some embodiments extending the life span of the cells.

- Any cells can be used in the screen. As long as the cells contain DNA to be targeted by the DNA-
15 damaging agent, they can be used to screen for compounds that mitigate or reverse toxicity mediated by the DNA-damaging agent. In some embodiments, the cells are mammalian cells. The cells can also be established cell lines commonly used in laboratory experiments.

- In some embodiments, the test compound can be provided at any suitable amount or
20 concentration, e.g., about 1-20 μ M, or about 2-10 μ M or about 5 μ M, or any other suitable concentration one of ordinary skill can determine through routine experimentation depending on the specific cells or the compound. The test compound can be any compound or agent of interest. The test compound can be a small molecule (e.g., having a molecular weight less than 1000 Da). The test compound can be from a library. In one example, the test compound may be selected from the
25 compounds listed in Table 1. The test compound can also be those disclosed in US Patent No. 8,362,277; U.S. Publication No. 2011/0015217; U.S. Publication No. 2012/0022096 and U.S. Publication No. 2013/0040977; U.S. Application No. 14/339,772 filed July 24, 2014; U.S. Provisional Patent Application No. 61/902,680 filed November 11, 2013 and U.S. Provisional Patent Application No. 61/912,625 filed December 6, 2013, all of which are hereby incorporated herein by reference in

their entirety, in particular the compounds disclosed in the Examples section.


The DNA-damaging agent is provided at can be provided at any suitable amount or concentration, e.g., about 0.01-20 μM , or about 0.05-10 μM , or about 0.1-1.5 μM , or about 0.5 μM , or any other
5 suitable concentration one of ordinary skill can determine through routine experimentation depending on the specific cells or the DNA-damaging agent.

In some embodiments, the DNA-damaging agent based screen can be combined with the NAMPT based screen, to further confirm the neuroprotective activity of the test compounds. For example,
10 compounds of interest identified from the DNA-damaging agent based screen can be further incubated with NAMPT, and an activity of the NAMPT can be measured thereafter, wherein an increase in the activity of the NAMPT additionally confirms the neuroprotective activity of the compound. Alternatively, compounds of interest identified from the NAMPT based screen can be further incubated with a population of cells and a DNA-damaging agent (the cells can be incubated
15 with the compound and the DNA-damaging agent together or separately in two sequential steps), and survival rate of the population of cells can be determined thereafter; wherein an increase in the survival rate compared to a control that is not treated with the compound is indicative of neuroprotective activity of the compound.

20 In some embodiments, the test compound having said neuroprotective activity can be further determined to bind and/or activate the NAMPT. Determining the test compound having said neuroprotective activity binds and/or activates the NAMPT can be done by any suitable methods such as mass spec and/or gel electrophoresis.

25 Compounds, Compound Forms and Salts

Compounds identified by the above screen methods are included in the present invention. In some embodiments, the compound can have formula (I):



(I)


wherein:

- 5 each of R^1 , R^2 , R^3 , and R^4 is independently selected from hydrogen, halo, hydroxyl, sulfhydryl, C_1 - C_6 alkoxy, C_1 - C_6 thioalkoxy, C_1 - C_6 haloalkoxy, C_1 - C_6 thiohaloalkoxy, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkynyl, cyclopropyl, $-N_3$, cyano, $-NH_2$, $-NH(C_1-C_6 \text{ alkyl})$, $-N(C_1-C_6 \text{ alkyl})_2$, $-NHC(O)(C_1-C_6 \text{ alkyl})$, nitro, $-C(O)O(C_1-C_6 \text{ alkyl})$, $-C(O)NH_2$, $-C(O)NH(C_1-C_6 \text{ alkyl})$, $-C(O)N(C_1-C_6 \text{ alkyl})_2$, $-S(O)_2NH_2$, $-S(O)_2NH(C_1-C_6 \text{ alkyl})$, and $-S(O)_2N(C_1-C_6 \text{ alkyl})_2$;

10

R and R' are defined according to (1), (2), (3) or (4) below:

- (1) R and R' together with C_2 and C_3 , respectively, form a fused phenyl ring having formula (II):



(II)

wherein each of R^5 , R^6 , R^7 , and R^8 is independently selected from hydrogen, halo, hydroxyl,

- 15 sulfhydryl, C_1 - C_6 alkoxy, C_1 - C_6 thioalkoxy, C_1 - C_6 haloalkoxy, C_1 - C_6 thiohaloalkoxy, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkynyl, cyclopropyl, $-N_3$, cyano, $-NH_2$, $-NH(C_1-C_6 \text{ alkyl})$, $-N(C_1-C_6 \text{ alkyl})_2$, $-NHC(O)(C_1-C_6 \text{ alkyl})$, nitro, $-C(O)O(C_1-C_6 \text{ alkyl})$, $-C(O)NH_2$, $-C(O)NH(C_1-C_6 \text{ alkyl})$, $-C(O)N(C_1-C_6 \text{ alkyl})_2$, $-S(O)_2NH_2$, -

$S(O)_2NH(C_1-C_6 \text{ alkyl})$, and $-S(O)_2N(C_1-C_6 \text{ alkyl})_2$; or

(2) R and R' together with C₂ and C₃, respectively, form a fused heteroaryl ring containing 6 ring atoms, wherein from 1-2 independently selected ring atoms is N; and wherein said heteroaryl ring is optionally substituted with from 1-2 independently selected R^b; or

5 (3) R and R' together with C₂ and C₃, respectively, form a fused heterocyclic ring containing from 5-6 ring atoms, wherein from 1-2 of the ring atoms is independently selected from N, NH, N(C₁-C₆ alkyl), NC(O)(C₁-C₆ alkyl), O, and S; and wherein said heterocyclic ring is optionally substituted with from 1-3 independently selected R^a; or

(4) each of R and R' is, independently, hydrogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

10 each of L¹ and L² is, independently, C₁-C₃ alkylene, which is optionally substituted with from 1-2 independently selected R^c;

A is:

15 (i) CR^{A1}R^{A2}, wherein each of R^{A1} and R^{A2} is independently selected from hydrogen, halo, C₁-C₃ alkyl, OR⁹, wherein R⁹ is hydrogen or C₁-C₃ alkyl that is optionally substituted with hydroxyl or C₁-C₃ alkoxy, or a double bond formed between A and one of L¹ and L²; or

(ii) C=O; or

(iii) C₃-C₅ cycloalkylene that is (a) substituted with 1 oxo; and (b) optionally further substituted with from 1-4 independently selected R^a; or

20 (iv) heterocycloalkylene containing from 3-5 ring atoms, wherein from 1-2 of the ring atoms is independently selected from N, NH, N(C₁-C₃ alkyl), O, and S; and wherein said heterocycloalkylene is (a) substituted with 1 oxo; and (b) is optionally further substituted with from 1-4 independently selected R^a;

25 Z is:

(i) -NR¹⁰R¹¹; or

(ii) -C(O)NR¹⁰R¹¹; or

(iii) -OR¹²; or

(iv) -S(O)_nR¹³, wherein n is 0, 1, or 2; or

(v) heterocycloalkenyl containing from 5-6 ring atoms, wherein from 1-3 of the ring atoms is independently selected from N, NH, N(C₁-C₆ alkyl), NC(O)(C₁-C₆ alkyl), O, and S; and wherein said heterocycloalkenyl is optionally substituted with from 1-4 independently selected R^a; or

(vi) C₆-C₁₀ aryl that is optionally substituted with from 1-4 independently selected R^b; or

(vii) heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(C₁-C₃ alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 independently selected R^b; or

(viii) C₈-C₁₄ arylcycloalkyl, wherein:

(1) the aryl portion is optionally substituted with from 1-4 independently selected R^b,

and

(2) the cycloalkyl portion is optionally substituted with from 1-4 independently selected R^a; or

(ix) arylheterocyclyl containing from 8-14 ring atoms, wherein:

(1) the aryl portion from is optionally substituted with from 1-4 independently selected R^b, and

(2) from 1-2 of the ring atoms of the heterocyclyl portion is independently selected from N, NH, N(C₁-C₆ alkyl), NC(O)(C₁-C₆ alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R^a; or

(x) heteroarylheterocyclyl containing from 8-14 ring atoms, wherein:

(1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(C₁-C₃ alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R^b; and

(2) from 1-2 of the ring atoms of the heterocyclyl portion is independently selected from N, NH, N(C₁-C₆ alkyl), NC(O)(C₁-C₆ alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R^a; or

(xi) heteroarylcyloalkyl containing from 8-14 ring atoms, wherein:

(1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(C₁-C₃ alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R^b; and

(2) the cycloalkyl portion is optionally substituted with from 1-4 independently selected R^a ;

each of R^{10} and R^{11} is independently selected from the substituents delineated collectively in (a) through (i) below:

(a) hydrogen;

(b) C_6 - C_{10} aryl that is optionally substituted with from 1-4 R^b ;

(c) heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, $N(C_1$ - C_3 alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 R^b ;

(d) C_1 - C_6 alkyl or C_1 - C_6 haloalkyl, each of which is optionally substituted with from 1-3 R^d ;

(e) $-C(O)(C_1$ - C_6 alkyl), $-C(O)(C_1$ - C_6 haloalkyl), $-C(O)O(C_1$ - C_6 alkyl), $-S(O)_2(C_1$ - C_6 alkyl), $-S(O)_2(C_6$ - C_{10} aryl), or $-S(O)_2(C_1$ - C_{13} heteroaryl), wherein the C_6 - C_{10} aryl and C_1 - C_{13} heteroaryl are each independently optionally substituted with 1-4 R^b ;

(f) C_2 - C_6 alkenyl or C_2 - C_6 alkynyl;

(g) C_8 - C_{14} arylcycloalkyl, wherein:

(1) the aryl portion is optionally substituted with from 1-4 independently selected R^b , and

(2) the cycloalkyl portion is optionally substituted with from 1-4 independently selected R^a ;

(h) arylheterocyclyl containing from 8-14 ring atoms, wherein:

(1) the aryl portion from is optionally substituted with from 1-4 independently selected R^b , and

(2) from 1-2 of the ring atoms of the heterocyclyl portion is independently selected from N, NH, $N(C_1$ - C_6 alkyl), $NC(O)(C_1$ - C_6 alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R^a ;

(i) heteroarylheterocyclyl containing from 8-14 ring atoms, wherein:

(1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, $N(C_1$ - C_3 alkyl), O, and S; and wherein said heteroaryl portion is optionally

substituted with from 1-3 independently selected R^b ; and

(2) from 1-2 of the ring atoms of the heterocyclyl portion is independently selected from N, NH, $N(C_1-C_6 \text{ alkyl})$, $NC(O)(C_1-C_6 \text{ alkyl})$, O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R^a ;

(j) heteroarylcycloalkyl containing from 8-14 ring atoms, wherein:

(1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, $N(C_1-C_3 \text{ alkyl})$, O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R^b ; and

(2) the cycloalkyl portion is optionally substituted with from 1-4 independently selected R^a ;

(k) C_3-C_8 cycloalkyl or C_3-C_8 cycloalkenyl, each of which is optionally substituted with from 1-4 independently selected R^a ; and

(l) C_7-C_{12} aralkyl, wherein the aryl portion is optionally substituted with from 1-4 independently selected R^b ,

provided that one of R^{10} and R^{11} must be selected from (b), (c), (g), (h), (i), (j), and (k);

R^{12} is:

(i) C_6-C_{10} aryl that is optionally substituted with from 1-4 R^b ; or

(ii) heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, $N(C_1-C_3 \text{ alkyl})$, O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 R^b ; or

(iii) C_1-C_6 alkyl or C_1-C_6 haloalkyl, each of which is substituted with from 1-3 R^d ; or

(iv) C_8-C_{14} arylcycloalkyl, wherein:

(1) the aryl portion is optionally substituted with from 1-4 independently selected R^b , and

(2) the cycloalkyl portion is optionally substituted with from 1-4 independently selected R^a ; or

(v) arylheterocyclyl containing from 8-14 ring atoms, wherein:

(1) the aryl portion from is optionally substituted with from 1-4 independently

selected R^b, and

(2) from 1-2 of the ring atoms of the heterocyclyl portion is independently selected from N, NH, N(C₁-C₆ alkyl), NC(O)(C₁-C₆ alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R^a; or

5 (vi) heteroarylheterocyclyl containing from 8-14 ring atoms, wherein:

(1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(C₁-C₃ alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R^b; and

10 (2) from 1-2 of the ring atoms of the heterocyclyl portion is independently selected from N, NH, N(C₁-C₆ alkyl), NC(O)(C₁-C₆ alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R^a;

or

(vii) heteroarylcycloalkyl containing from 8-14 ring atoms, wherein:

15 (1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(C₁-C₃ alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R^b; and

(2) the cycloalkyl portion is optionally substituted with from 1-4 independently selected R^a;

20 R¹³ is:

(i) C₆-C₁₀ aryl that is optionally substituted with from 1-4 R^b; or

(ii) heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(C₁-C₃ alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 R^b; or

25 (iii) C₈-C₁₄ arylcycloalkyl, wherein:

(1) the aryl portion is optionally substituted with from 1-4 independently selected R^b, and

(2) the cycloalkyl portion is optionally substituted with from 1-4 independently selected R^a;

or

(iv) arylheterocyclyl containing from 8-14 ring atoms, wherein:

(1) the aryl portion from is optionally substituted with from 1-4 independently selected R^b , and

(2) from 1-2 of the ring atoms of the heterocyclyl portion is independently selected from N, NH, N(C₁-C₆ alkyl), NC(O)(C₁-C₆ alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R^a ;

or

(v) heteroarylheterocyclyl containing from 8-14 ring atoms, wherein:

(1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(C₁-C₃ alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R^b ; and

(2) from 1-2 of the ring atoms of the heterocyclyl portion is independently selected from N, NH, N(C₁-C₆ alkyl), NC(O)(C₁-C₆ alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R^a ;

or

(vi) heteroarylcycloalkyl containing from 8-14 ring atoms, wherein:

(1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(C₁-C₃ alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R^b ; and

(2) the cycloalkyl portion is optionally substituted with from 1-4 independently selected R^a ;

R^a at each occurrence is, independently selected from halo, hydroxyl, C₁-C₆ alkoxy, C₁-C₆ thioalkoxy, C₁-C₆ haloalkoxy, C₁-C₆ thiohaloalkoxy, oxo, thioxo, =NH, =N(C₁-C₆ alkyl), C₁-C₆ alkyl, C₁-C₆ haloalkyl, -NH₂, -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, -NHC(O)(C₁-C₆ alkyl), and cyano;

R^b at each occurrence is independently selected from the substituents delineated in (aa) through (dd) below:

(aa) C₁-C₆ alkoxy; C₁-C₆ haloalkoxy; C₁-C₆ thioalkoxy; C₁-C₆ thiohaloalkoxy; -O-(CH₂)₁₋₃-[O(CH₂)₁₋₃]₁₋₃-H; -C₁-C₆ alkyl, C₁-C₆ haloalkyl, -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, -NHC(O)(C₁-C₆ alkyl), wherein the alkyl portion of each is optionally substituted with from 1-3 independently selected R^e;

(bb) halo; hydroxyl; cyano; nitro; -NH₂; azido; sulfhydryl; C₂-C₆ alkenyl; C₂-C₆ alkynyl; -C(O)H; -C(O)(C₁-C₆ alkyl); -C(O)(C₁-C₆ haloalkyl); -C(O)OH; -C(O)O(C₁-C₆ alkyl); -C(O)NH₂; -C(O)NH(C₁-C₆ alkyl); -C(O)N(C₁-C₆ alkyl)₂; -SO₂(C₁-C₆ alkyl); -SO₂NH₂; -SO₂NH(C₁-C₆ alkyl); -SO₂N(C₁-C₆ alkyl)₂;

(cc) C₃-C₆ cycloalkyl or heterocyclyl containing from 5-6 ring atoms, wherein from 1-2 of the ring atoms of the heterocyclyl is independently selected from N, NH, N(C₁-C₆ alkyl), NC(O)(C₁-C₆ alkyl), O, and S; and wherein each of said phenyl and heterocyclyl is optionally substituted with from 1-3 independently selected R^a; and

(dd) phenyl or heteroaryl containing from 5-6 ring atoms, wherein from 1-2 of the ring atoms of the heteroaryl is independently selected from N, NH, N(C₁-C₃ alkyl), O, and S; wherein each of said phenyl and heteroaryl is optionally substituted with from 1-3 substituents independently selected from halo; hydroxyl; cyano; nitro; -NH₂; -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, -NHC(O)(C₁-C₆ alkyl), C₁-C₆ alkoxy; C₁-C₆ haloalkoxy; C₁-C₆ thioalkoxy; C₁-C₆ thiohaloalkoxy; C₁-C₆ alkyl, and C₁-C₆ haloalkyl;

R^c at each occurrence is, independently selected from halo, C₁-C₆ alkoxy, C₁-C₆ thioalkoxy, C₁-C₆ haloalkoxy, C₁-C₆ thiohaloalkoxy, C₁-C₆ alkyl, C₁-C₆ haloalkyl, -NH₂, -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, -NHC(O)(C₁-C₆ alkyl), and cyano;

R^d at each occurrence is, independently selected from hydroxyl, C₁-C₆ alkoxy, C₁-C₆ thioalkoxy, C₁-C₆ haloalkoxy, C₁-C₆ thiohaloalkoxy, C₁-C₆ alkyl, C₁-C₆ haloalkyl, -NH₂, -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, -NHC(O)(C₁-C₆ alkyl), and cyano; and

R^e at each occurrence is, independently selected from hydroxyl, C₁-C₆ alkoxy; C₁-C₆ thioalkoxy; C₁-C₆ haloalkoxy; C₁-C₆ thiohaloalkoxy; -NH₂; -NH(C₁-C₆ alkyl); -N(C₁-C₆ alkyl)₂; -NHC(O)(C₁-C₆ alkyl); cyano;

-C(O)H; -C(O)(C₁-C₆ alkyl); -C(O)(C₁-C₆ haloalkyl); -C(O)OH; -C(O)O(C₁-C₆ alkyl); -C(O)NH₂; -C(O)NH(C₁-C₆ alkyl); -C(O)N(C₁-C₆ alkyl)₂; -SO₂(C₁-C₆ alkyl); -SO₂NH₂; -SO₂NH(C₁-C₆ alkyl); -SO₂N(C₁-C₆ alkyl)₂; and L³-(C₁-C₆ alkylene)-biotin, where in L³ is a -O-, -NH-, -NCH₃-, -C(O)-, -C(O)NH-, -C(O)NCH₃-, -NHC(O)-, or -NCH₃C(O)-.

5

In some embodiments, one or more of (A), (B), or (C) apply:

(A) Provided that when R and R' are defined according to definition (3), then:

(i) each of L¹ and L² must be C₁-C₃ alkylene, which is optionally substituted with from 1-2

independently selected R^c when A is CH₂; or

10 (ii) -L¹-A-L² cannot be -CH₂-CH₂- when Z is 2-methylpyridyl; or

(iii) Z must be other than heteroaryl containing from 5-14 (e.g., 5-6 or 6) ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(C₁-C₃ alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 independently selected R^b; e.g., other than substituted pyridyl, e.g., other than pyridyl substituted with C₁-C₃ alkyl (e.g., CH₃), e.g., other than 2 or 6-methylpyridyl.

15


(B) Each of R¹⁰ and R¹¹ cannot be optionally substituted naphthyl (e.g., each of R¹⁰ and R¹¹ cannot be unsubstituted naphthyl). In embodiments, each of R¹⁰ and R¹¹ is other than optionally substituted naphthyl (e.g., unsubstituted naphthyl) when R and R' are defined according to definitions (1), (2), and (4); and A is CR^{A1}R^{A2} (e.g., CHOR⁹, e.g., CHOH), and each of L¹ and L² is C₁-C₃ alkylene (e.g., each of L¹ and L² is CH₂).

20

(C) R¹² and/or R¹³ cannot be substituted phenyl. In embodiments, R¹² and/or R¹³ cannot be substituted phenyl when R and R' are defined according to definition (1); and A is CR^{A1}R^{A2} (e.g., CHOR⁹, e.g., CHOH), and each of L¹ and L² is C₁-C₃ alkylene (e.g., each of L¹ and L² is CH₂).

25 In some embodiments, (A), (B), or (C) applies. In other embodiments, (A) and (B); or (A) and (C); or (B) and (C) applies. In still other embodiments, (A), (B), and (C) apply.

In certain embodiments, the compounds are of formula (III):



(III)

in which R^1 , R^2 , R^3 , R^4 , L^1 , L^2 , A, and Z can be as defined anywhere herein.

5 In some embodiments, one or more of the following can apply:

each of L^1 and L^2 is CH_2 ;

A is $CR^{A1}R^{A2}$, wherein one of R^{A1} and R^{A2} is OR^9 , and the other is hydrogen;

Z is $-NR^{10}R^{11}$; and

each of R^{10} and R^{11} is independently selected from:

- 10 (a) hydrogen;
- (b) C_6 - C_{10} aryl that is optionally substituted with from 1-4 R^b ;
- (c) heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, $N(C_1$ - C_3 alkyl), O, and S, and wherein said heteroaryl is optionally substituted with from 1-4 R^b ; e.g., pyridyl optionally substituted with 1 R^b ; e.g., 2-methoxypyridyl;
- 15 (d) C_1 - C_6 alkyl or C_1 - C_6 haloalkyl, each of which is optionally substituted with from 1-3 R^d ;
- (f) C_2 - C_6 alkenyl or C_2 - C_6 alkynyl.

20 In embodiments, one or more of the following may apply:

- provided that R^3 and R^6 cannot both be hydrogen when A is CH_2 , and R and R' are defined according to definition (1);

- provided that R^3 cannot be hydrogen when A is CH_2 , and R and R' are defined according to definition (2);
- provided that R^3 and R^6 cannot both be chloro when A is CH_2 , R and R' are defined according to definition (1), Z is $-OR^{12}$, and R^{12} is unsubstituted phenyl;
- 5 • provided that R^3 and R^6 cannot both be bromo when A is CH_2 , R and R' are defined according to definition (1), Z is $-OR^{12}$, and R^{12} is phenyl that is substituted with pyridyl or alkyl that is substituted with from 1-3 R^e ;
- provided that R^3 and R^6 cannot both be hydrogen when A is $CH(CH_3)$, R and R' are defined according to definition (1), Z is $NR^{10}R^{11}$, R^{10} is CH_3 , and R^{11} is unsubstituted phenyl;
- 10 • provided that when A is $CR^{A1}R^{A2}$, and one of R^{A1} and R^{A2} is OH (i.e., R^9 is H), then the other of R^{A1} and R^{A2} is C_1 - C_3 alkyl.

In certain embodiments, one or more of the following apply, e.g., when A is $CHOH$ and Z is $NR^{10}R^{11}$:

- 15 • each of R^3 and R^6 is CH_3 ; and/or each of R^3 and R^6 is bromo; and/or each of R^3 and R^6 is chloro; and/or one of R^3 and R^6 is CH_3 (e.g., R^6), and the other is bromo (e.g., R^3);
- each of R^{10} and R^{11} is other than hydrogen;
- each of R^{10} and R^{11} is hydrogen;
- one of R^{10} and R^{11} is heteroaryl (optionally substituted) as defined herein; and
- 20 • L^1 and/or L^2 is C_2 - C_3 alkylene (optionally substituted).

In certain embodiments, when R^3 and R^6 are both halo, one of R^{A1} and R^{A2} is OH and the other is hydrogen, Z is $-NHR^{10}$, and R^{10} is C_6 - C_{10} aryl that is optionally substituted with 1 to 4 R^b , then R^{10} is unsubstituted phenyl or phenyl substituted with 1 R^b .

- 25 In some embodiments, one of R^{10} and R^{11} must be (b) or (c).

The compound, in some embodiments, can be (+) or (-) (*dextrorotatory*) when in the presence of plane polarized light. In some embodiments, the (+) (*dextrorotatory*) compound can be substantially free of (e.g., containing less than about 5% of, less than about 2% of, less than about 1%, less than

about 0.5%) a compound that is (*levorotatory*). In some embodiments, the (-) (*levorotatory*) compound can be substantially free of (e.g., containing less than about 5% of, less than about 2% of, less than about 1%, less than about 0.5%) a compound that is (+) (*dextrorotatory*).

- 5 In embodiments, the carbon attached to R^{A1} and R^{A2} is substituted with four different substituents (for purposes of clarification, these four substituents include R^{A1} and R^{A2}) and is therefore a stereogenic center.

10 In certain embodiments, the carbon attached to R^{A1} and R^{A2} is (*R*) configured, meaning that the carbon attached to R^{A1} and R^{A2} has the (*R*) configuration (Cahn Ingold Prelog sequence rules notation). Such compounds are sometimes referred to herein as an “(*R*)-configured compound” (this term also includes compounds that further contain one or more stereogenic centers in addition to the (*R*)- $CR^{A1}R^{A2}$ stereogenic center). In other embodiments, the carbon attached to R^{A1} and R^{A2} is (*S*) configured, meaning that the carbon attached to R^{A1} and R^{A2} has the (*S*) configuration (Cahn
15 Ingold Prelog sequence rules notation). Such compounds are sometimes referred to herein as an “(*S*)-configured compound” (this term also includes compounds that further contain one or more stereogenic centers in addition to the (*S*)- $CR^{A1}R^{A2}$ stereogenic center). In embodiments, the (*R*) configured compound (or salt, e.g., a pharmaceutically acceptable salt, thereof) is substantially free of (e.g., contains less than about 5% of, less than about 2% of, less than about 1%, less than about
20 0.5% of) a compound (or salt thereof as described herein) that is (*S*) configured at the carbon attached to R^{A1} and R^{A2} (i.e., a compound in which the carbon attached to R^{A1} and R^{A2} has the (*S*) configuration). For example, the (*R*) configured compound can be an (*R*)-enantiomer that is substantially free of its opposing (*S*) enantiomer. As another example, an (*R*) configured compound can be substantially free of a diastereomer in which the carbon attached to R^{A1} and R^{A2} has the (*S*)
25 configuration. In certain embodiments, the (*R*) configured compound can be additionally in substantially pure form (e.g., contains less than about 5% of, less than about 2% of, less than about 1%, less than about 0.5% of other substances, including, for example, one or more of other compounds). In embodiments, the (*S*) configured compound (or salt, e.g., a pharmaceutically acceptable salt, thereof) is substantially free of (e.g., contains less than about 5% of, less than about

2% of, less than about 1%, less than about 0.5% of) a compound (or salt thereof as described herein) that is (*R*) configured at the carbon attached to R^{A1} and R^{A2} (i.e., a compound in which the carbon attached to R^{A1} and R^{A2} has the (*R*) configuration). For example, the (*S*) configured compound can be an (*S*)-enantiomer that is substantially free of its opposing (*R*) enantiomer. As another example, the (*S*) configured compound can be substantially free of a diastereomer in which the carbon attached to R^{A1} and R^{A2} has the (*R*) configuration. In certain embodiments, the (*S*) configured compound can be additionally in substantially pure form (e.g., contains less than about 5% of, less than about 2% of, less than about 1%, less than about 0.5% of other substances, including, for example, one or more of other compounds).

The neuroprotective compound of the present invention can include any one or more compounds selected from:

R-1-(3,6-Dibromo-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)-propan-2-ol;
S-1-(3,6-Dibromo-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)-propan-2-ol;
 1-(3,6-dibromo-9H-carbazol-9-yl)-3-(2-iminopyridin-1(2H)-yl)propan-2-ol;
 1-(3,6-dibromo-9H-carbazol-9-yl)-3-(phenylthio)propan-2-ol;
 N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-hydroxypropyl)-N-(3-methoxyphenyl)acetamide;
 5-((3,6-dibromo-9H-carbazol-9-yl)methyl)-3-(3-methoxyphenyl)-oxazolidin-2-one;
 N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-3-methoxyaniline;
 1-(3,6-dibromo-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)-propan-2-one;
 N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-methoxypropyl)-3-methoxyaniline;
 1-(3,6-Dimethyl-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)propan-2-ol;
 1-(3-Bromo-6-methyl-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)-propan-2-ol;
 1-(3,6-Dichloro-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)propan-2-ol;
 1-(5-bromo-2,3-dimethyl-1H-indol-1-yl)-3-(phenylamino)propan-2-ol;
 1-(3,6-Dibromo-9H-pyrido[3,4-b]indol-9-yl)-3-(phenylamino)propan-2-ol;
 1-(3-Azidophenylamino)-3-(3,6-dibromo-9H-carbazol-9-yl)propan-2-ol;
 1,3-Bis(3,6-dibromo-9H-carbazol-9-yl)propan-2-ol;
 1-(9H-Carbazol-9-yl)-3-(3,6-dibromo-9H-carbazol-9-yl)propan-2-ol;

- 3-(3,6-Dibromo-9H-carbazol-9-yl)-2-hydroxy-N-(3-methoxyphenyl)-propanamide;
 Ethyl 5-(2-Hydroxy-3-(3-methoxyphenylamino)propyl)-8-methyl-3,4-dihydro-1H-pyrido[4,3-b]indole-2(5H)-carboxylate;
- 4-(3,6-dibromo-9H-carbazol-9-yl)-1-(phenylamino)butan-2-ol;
- 5 N-(3-(3,6-dibromo-9H-carbazol-9-yl)propyl)aniline;
- 1-(3,6-dibromo-9H-carbazol-9-yl)-4-(phenylamino)butan-2-ol;
- 1-(3,6-dibromo-9H-carbazol-9-yl)-3-(pyridin-2-ylamino)propan-2-ol;
- 1-(3,6-dibromo-9H-carbazol-9-yl)-3-((3-methoxyphenyl)(methyl)-amino)propan-2-ol;
- 3-(3,6-dibromo-9H-carbazol-9-yl)-1-(3-methoxyphenylamino)-1-(methylthio)propan-2-one;
- 10 3-amino-1-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-hydroxypropyl)pyridinium;
- 1-(3,6-dibromo-9H-carbazol-9-yl)-3-(pyrimidin-2-ylamino)propan-2-ol;
- N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-3-methoxy-N-methylaniline;
- 1-(3,6-dibromo-9H-carbazol-9-yl)-3-methoxypropan-2-ol;
- 1-(3,6-dibromo-9H-carbazol-9-yl)-4-phenylbutan-2-ol;
- 15 1-(3,6-dibromo-9H-carbazol-9-yl)-3-(1H-indol-1-yl)propan-2-ol;
- 3-(1-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-hydroxypropyl)-1H-1,2,3-triazol-4-yl)propan-1-ol;
- 1-(3,6-dibromo-9H-carbazol-9-yl)-3-(3-ethoxyphenylamino)propan-2-ol;
- 1-(3,6-dibromo-9H-carbazol-9-yl)-3-(3,5-dimethyl-1H-pyrazol-1-yl)propan-2-ol;
- 1-(3,6-dibromo-9H-carbazol-9-yl)-3-(phenylsulfinyl)propan-2-ol;
- 20 1-(3,6-dibromo-9H-carbazol-9-yl)-3-(phenylsulfonyl)propan-2-ol;
- 1-(3-bromo-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)propan-2-ol;
- N-(5-(3-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-hydroxypropylamino)phenoxy)pentyl)-2-(7-(dimethylamino)-2-oxo-2H-chromen-4-yl)acetamide;
- 1-(3,6-dibromo-9H-carbazol-9-yl)-3-phenoxypropan-2-ol;
- 25 N-(2-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-hydroxypropoxy)ethyl)-acetamide;
- 1-(3,6-dibromo-9H-carbazol-9-yl)-3-(pyridin-3-ylamino)propan-2-ol;
- 1-(3,6-dibromo-9H-carbazol-9-yl)-3-(pyridin-4-ylamino)propan-2-ol;
- 1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(phenylamino)propan-2-ol;
- N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2,2-difluoropropyl)-3-methoxyaniline;

- 1-(3,6-dibromo-9H-carbazol-9-yl)-3-phenoxypropan-2-ol;
1-(3,6-dibromo-9H-carbazol-9-yl)-3-(phenylamino)propan-2-ol;
1-(3,6-dibromo-9H-carbazol-9-yl)-3-(o-tolylamino)propan-2-ol;
1-(3,6-dibromo-9H-carbazol-9-yl)-3-(m-tolylamino)propan-2-ol;
5 1-(3,6-dibromo-9H-carbazol-9-yl)-3-(2-methoxyphenylamino)propan-2-ol;
1-(3,6-dibromo-9H-carbazol-9-yl)-3-(naphthalen-1-ylamino)propan-2-ol;
1-(4-bromophenylamino)-3-(3,6-dichloro-9H-carbazol-9-yl)propan-2-ol;
1-(4-bromophenylamino)-3-(3,6-dibromo-9H-carbazol-9-yl)propan-2-ol;
1-(3,6-dibromo-9H-carbazol-9-yl)-3-(4-ethoxyphenylamino)propan-2-ol;
10 1-(4-chlorophenylamino)-3-(3,6-dibromo-9H-carbazol-9-yl)propan-2-ol;
1-(3,6-dibromo-9H-carbazol-9-yl)-3-(phenethylamino)propan-2-ol;
1-(3,6-dibromo-9H-carbazol-9-yl)-3-(2-hydroxyethylamino)propan-2-ol;
1-(3,6-dibromo-9H-carbazol-9-yl)-3-(2,4-dimethoxyphenylamino)propan-2-ol;
1-(3,6-dibromo-9H-carbazol-9-yl)-3-(2,3-dimethylphenylamino)propan-2-ol;
15 1-(2-chlorophenylamino)-3-(3,6-dibromo-9H-carbazol-9-yl)propan-2-ol;
1-(tert-butylamino)-3-(3,6-dibromo-9H-carbazol-9-yl)propan-2-ol;
1-(3,6-dibromo-9H-carbazol-9-yl)-3-(isopropylamino)propan-2-ol;
1-(3,6-dibromo-9H-carbazol-9-yl)-3-(4-methoxyphenylamino)propan-2-ol;
1-(3,6-dibromo-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)propan-2-ol;
20 1-(3,6-dibromo-9H-carbazol-9-yl)-3-(m-tolylamino)propan-2-ol;
1-(3,6-dibromo-9H-carbazol-9-yl)-3-(3,5-dimethylphenylamino)propan-2-ol;
1-(3,6-dibromo-9H-carbazol-9-yl)-3-(3,4-dimethylphenylamino)propan-2-ol;
1-(3,6-dibromo-9H-carbazol-9-yl)-3-(3,4-dimethylphenylamino)propan-2-ol;
1-(3,6-dibromo-9H-carbazol-9-yl)-3-(2,5-dimethylphenylamino)propan-2-ol;
25 1-(4-bromophenylamino)-3-(2,3-dimethyl-1H-indol-1-yl)propan-2-ol;
1-(2,3-dimethyl-1H-indol-1-yl)-3-(4-methoxyphenylamino)propan-2-ol;
1-(2,3-dimethyl-1H-indol-1-yl)-3-(4-ethoxyphenylamino)propan-2-ol;
1-(2,3-dimethyl-1H-indol-1-yl)-3-(p-tolylamino)propan-2-ol;
1-(2,3-dimethyl-1H-indol-1-yl)-3-(phenylamino)propan-2-ol oxalate;

- 1-(1H-indol-1-yl)-3-(4-methoxyphenylamino)propan-2-ol hydrochloride;
1-(1H-indol-1-yl)-3-(phenylamino)propan-2-ol oxalate;
1-(3,4-dihydro-1H-carbazol-9(2H)-yl)-3-(m-tolylamino)propan-2-ol;
1-(9H-carbazol-9-yl)-3-(phenylamino)propan-2-ol;
5 1-(3,6-dichloro-9H-carbazol-9-yl)-3-(phenylamino)propan-2-ol;
1-(9H-carbazol-9-yl)-3-(p-tolylamino)propan-2-ol;
1-(3,6-dichloro-9H-carbazol-9-yl)-3-(p-tolylamino)propan-2-ol;
1-(3,6-dibromo-9H-carbazol-9-yl)-3-(p-tolylamino)propan-2-ol;
N-(4-(3-(9H-carbazol-9-yl)-2-hydroxypropoxy)phenyl)acetamide;
10 1-(9H-carbazol-9-yl)-3-phenoxypropan-2-ol;
1-(9H-carbazol-9-yl)-3-(4-methoxyphenylamino)propan-2-ol;
1-(benzylamino)-3-(9H-carbazol-9-yl)propan-2-ol;
methyl 4-(3-(9H-carbazol-9-yl)-2-hydroxypropoxy)benzoate;
1-(9H-carbazol-9-yl)-3-(4-methoxyphenoxy)propan-2-ol;
15 1-amino-3-(3,6-dibromo-9H-carbazol-9-yl)propan-2-ol;
(S)-1-(3,6-dibromo-9H-carbazol-9-yl)-3-phenoxypropan-2-ol;
(R)-1-(3,6-dibromo-9H-carbazol-9-yl)-3-phenoxypropan-2-ol;
3,6-dibromo-9-(2-fluoro-3-phenoxypropyl)-9H-carbazole;
1-(3,6-dibromo-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)-2-methylpropan-2-ol;
20 1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(3-methoxyphenylamino)propan-2-ol;
1-(4-azidophenylamino)-3-(3,6-dibromo-9H-carbazol-9-yl)propan-2-ol;
1-(3-azido-6-bromo-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)propan-2-ol;
1-(3,6-dibromo-9H-carbazol-9-yl)-3-(4-methoxyphenoxy)propan-2-ol;
25 1-(3,6-dichloro-9H-carbazol-9-yl)-3-(phenylsulfonyl)propan-2-ol;
3,6-dibromo-9-(2-fluoro-3-(phenylsulfonyl)propyl)-9H-carbazole;
S)-1-(3,6-dibromo-9H-carbazol-9-yl)-3-(phenylsulfonyl)propan-2-ol;
(R)-1-(3,6-dibromo-9H-carbazol-9-yl)-3-(phenylsulfonyl)propan-2-ol;
1-(3,6-dicyclopropyl-9H-carbazol-9-yl)-3-(phenylamino)propan-2-ol;

- 1-(3,6-diiodo-9H-carbazol-9-yl)-3-(phenylamino)propan-2-ol;
 1-(3,6-diethynyl-9H-carbazol-9-yl)-3-(3-methoxyphenylamino) propan-2-ol;
 9-(2-hydroxy-3-(3-methoxyphenylamino)propyl)-9H-carbazole-3,6-dicarbonitrile;
 N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)aniline;
 5 3,6-dibromo-9-(2,2-difluoro-3-phenoxypropyl)-9H-carbazole;
 N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-4-methoxyaniline;
 N-(2-bromo-3-(3,6-dibromo-9H-carbazol-9-yl)propyl)-N-(4-methoxyphenyl)-4-nitrobenzenesulfonamide;
 Ethyl 2-(4-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropylamino)phenoxy)acetate; and
 10 N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-4-(2-(2-methoxyethoxy)ethoxy)aniline;
 N-(2-(2-(4-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropylamino)phenoxy)acetamido)ethyl)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide;
 2-(4-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropylamino)phenoxy)-N,N-
 15 dimethylacetamide;
 2-(4-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropylamino)phenoxy)-N-(2-hydroxyethyl)acetamide;
 1-(bis(4-bromophenyl)amino)-3-(phenylamino)propan-2-ol;
 (E)-3,6-dibromo-9-(3-phenoxyallyl)-9H-carbazole;
 20 (E)-3,6-dibromo-9-(3-phenoxyprop-1-en-1-yl)-9H-carbazole;
 1-(3,6-bis(trifluoromethyl)-9H-carbazol-9-yl)-3-(phenylamino)propan-2-ol;
 1-(2,8-Dibromo-10,11-dihydro-5H-dibenzo[*b,f*]azepin-5-yl)-3-(3-methoxyphenylamino)propan-2-ol;
 1-(3,6-Dibromo-9H-carbazol-9-yl)-3-(3-methoxyphenylthio)propan-2-ol;
 25 1-(3,6-Dibromo-9H-carbazol-9-yl)-3-(4-methoxyphenylthio)propan-2-ol;
 3,6-Dibromo-9-(2-fluoro-3-(3-methoxyphenylthio)propyl)-9H-carbazole;
 3,6-Dibromo-9-(2-fluoro-3-(4-methoxyphenylthio)propyl)-9H-carbazole;
 3,6-Dibromo-9-(2-fluoro-3-(3-methoxyphenylsulfonyl)propyl)-9H-carbazole;
 1-(3,6-Dibromo-9H-carbazol-9-yl)-3-(3-methoxyphenylsulfonyl)propan-2-ol;

- 3,6-Dibromo-9-(2-fluoro-3-(4-methoxyphenylsulfonyl)propyl)-9H-carbazole;
 1-(3,6-Dibromo-9H-carbazol-9-yl)-3-(4-methoxyphenylsulfonyl)propan-2-ol;
 3-(3-(3,6-Dibromo-9H-carbazol-9-yl)-2-hydroxypropylthio)phenol;
 4-(3-(3,6-Dibromo-9H-carbazol-9-yl)-2-hydroxypropylthio)phenol;
 5 3-(3-(3,6-Dibromo-9H-carbazol-9-yl)-2-hydroxypropylsulfonyl)phenol;
 4-(3-(3,6-Dibromo-9H-carbazol-9-yl)-2-hydroxypropylsulfonyl)phenol;
 1-(3-Aminophenylthio)-3-(3,6-dibromo-9H-carbazol-9-yl)propan-2-ol;
 1-(4-Aminophenylthio)-3-(3,6-dibromo-9H-carbazol-9-yl)propan-2-ol;
 1-(3,6-dibromo-9H-carbazol-9-yl)-3-phenoxypropan-2-amine;
 10 *N*-Benzyl-2-(3-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-hydroxypropylthio)-phenoxy)acetamide;
N-Benzyl-2-(4-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-hydroxypropylthio)-phenoxy)acetamide;
 3-(3-(3,6-Dibromo-9H-carbazol-9-yl)-2-fluoropropylsulfonyl)phenol; *N*-Benzyl-2-(3-(3-(3,6-
 dibromo-9H-carbazol-9-yl)-2-hydroxypropylsulfonyl)-phenoxy)acetamide;
 4-(3-(3,6-Dibromo-9H-carbazol-9-yl)-2-fluoropropylsulfonyl)phenol;
 15 5-(5-(3-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-hydroxypropylamino)phenoxy)pentylcarbamoyle)-
 2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid;
 1-(8-bromo-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-phenoxypropan-2-ol;
 1-(8-bromo-2-cyclopropyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-phenoxypropan-2-
 ol;
 20 8-bromo-5-(2-hydroxy-3-phenoxypropyl)-3,4-dihydro-1H-pyrido[4,3-b]indole-2(5H)-
 carbonitrile;
 8-bromo-5-(2-fluoro-3-phenoxypropyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;
 1-(cyclohexylamino)-3-(3,6-dibromo-9H-carbazol-9-yl)propan-2-ol;
 (9-(2-hydroxy-3-(phenylthio)propyl)-9H-carbazole-3,6-dicarbonitrile;
 25 9-(2-hydroxy-3-phenoxypropyl)-9H-carbazole-3,6-dicarbonitrile;
R-N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-3-methoxyaniline
S-N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-3-methoxyaniline
N-(2-(3,6-dibromo-9H-carbazol-9-yl)ethyl)aniline;
 2-(6-Amino-3-imino-3H-xanthen-9-yl)-4-(6-(5-(3-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-

hydroxypropylamino)phenoxy)pentylamino)-6-oxohexylcarbamoyl)benzoic acid AND 2-(6-amino-3-imino-3H-xanthen-9-yl)-5-(6-(5-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-

hydroxypropylamino)phenoxy)pentylamino)-6-oxohexylcarbamoyl)benzoic acid;

1-(8-bromo-2-methyl-3,4-dihydro-1H-pyrido[4,3-*b*]indol-5(2*H*)-yl)-3-phenoxypropan-2-ol;

5 6-((4-bromophenyl)(2-hydroxy-3-phenoxypropyl)amino)nicotinonitrile;

1-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-hydroxypropyl)pyridin-2(1*H*)-one;

9-(2-hydroxy-3-phenoxypropyl)-9H-carbazole-3-carbonitrile;

tert-butyl (5-(4-((3-(3,6-dibromo-9H-carbazol-9-yl)-2-hydroxypropyl)sulfonyl)

phenoxy)pentyl)carbamate;

10 6-bromo-9-(2-hydroxy-3-phenoxypropyl)-9H-carbazole-3-carbonitrile;

6-bromo-9-(2-hydroxy-3-phenoxypropyl)-9H-carbazole-3-carboxamide;

1-(3,6-dibromo-9H-carbazol-9-yl)-3-(pyridin-2-yloxy)propan-2-ol;

methyl 6-bromo-9-(2-hydroxy-3-phenoxypropyl)-9H-carbazole-3-carboxylate;

6-bromo-9-(2-hydroxy-3-phenoxypropyl)-9H-carbazole-3-carboxylic acid;

15 6-bromo-9-(2-hydroxy-3-phenoxypropyl)-9H-pyrido[2,3-*b*]indole-3-carbonitrile;

9-(2-hydroxy-3-phenoxypropyl)-9H-pyrido[2,3-*b*]indole-3-carbonitrile;

tert-butyl 3-(2-(2-(2-(3-((3-(3,6-dibromo-9H-carbazol-9-yl)-2-

hydroxypropyl)amino)phenoxy)ethoxy)ethoxy)ethoxy)propanoate;

1-(3,6-dibromo-1,4-dimethoxy-9H-carbazol-9-yl)-3-(phenylamino)propan-2-ol;

20 1-(3,6-dibromo-1,8-dimethyl-9H-carbazol-9-yl)-3-(phenylamino)propan-2-ol;

2-(3,6-dibromo-9H-carbazol-9-yl)acetic acid;

1-(6-bromo-3-methoxy-1-methyl-9H-carbazol-9-yl)-3-(phenylamino)propan-2-ol;

1-(4,6-dibromo-3-methoxy-1-methyl-9H-carbazol-9-yl)-3-(phenylamino)propan-2-ol;

1-(3,6-dibromo-4-methoxy-9H-carbazol-9-yl)-3-(phenylamino)propan-2-ol;

25 9-(2-hydroxy-3-phenoxypropyl)-9H-pyrido[3,4-*b*]indole-3-carboxylic acid;

6-bromo-9-(2-hydroxy-3-phenoxypropyl)-9H-pyrido[3,4-*b*]indole-3-carboxylic acid;

ethyl 6-bromo-9-(2-hydroxy-3-phenoxypropyl)-9H-pyrido[3,4-*b*]indole-3-carboxylate;

9-(2-fluoro-3-phenoxypropyl)-9H-carbazole-3,6-dicarbonitrile;

9-(2-hydroxy-2-methyl-3-phenoxypropyl)-9H-carbazole-3,6-dicarbonitrile;

- 1-(cyclohexyloxy)-3-(3,6-dibromo-9H-carbazol-9-yl)propan-2-ol;
(E)-N-(3-(3,6-dibromo-9H-carbazol-9-yl)prop-1-en-1-yl)-1,1,1-trifluoro-N-(3-methoxyphenyl)methanesulfonamide;
- 1-(3,6-dibromo-9H-pyrido[2,3-b]indol-9-yl)-3-phenoxypropan-2-ol;
- 5 1-(3,6-dibromo-9H-carbazol-9-yl)-3-((6-methoxypyridin-2-yl)amino)propan-2-ol;
1-(8-bromo-5H-pyrido[4,3-b]indol-5-yl)-3-phenoxypropan-2-ol;
6-bromo-9-(2-hydroxy-3-phenoxypropyl)-9H-pyrido[3,4-b]indole-3-carboxamide;
8-bromo-5-(2-hydroxy-3-phenoxypropyl)-5H-pyrido[4,3-b]indole 2-oxide;
8-bromo-5-(2-hydroxy-3-phenoxypropyl)-5H-pyrido[3,2-b]indole 1-oxide;
- 10 (6-bromo-9H-pyrido[3,4-b]indol-3-yl)methanol;
ethyl 6-bromo-9H-pyrido[3,4-b]indole-3-carboxylate;
tert-butyl (3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)carbamate;
2-(3,6-dibromo-9H-carbazol-9-yl)-N-methylacetamide;
3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropan-1-amine hydrochloride;
- 15 N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)acetamide;
2-(3,6-dibromo-9H-carbazol-9-yl)propanamide;
6-bromo-9H-pyrido[3,4-b]indole-3-carbonitrile;
6-bromo-3-methyl-9H-pyrido[3,4-b]indole;
methyl (2-(3,6-dibromo-9H-carbazol-9-yl)acetyl)carbamate;
- 20 N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-1,1,1-trifluoro-N-(3-methoxyphenyl)methanesulfonamide;
N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine;
N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-hydroxypropyl)-1,1,1-trifluoro-N-(3-methoxyphenyl)methanesulfonamide;
- 25 1-(3,6-dibromo-9H-carbazol-9-yl)-3-((4-methoxybenzyl)(3-methoxyphenyl)amino)propan-2-ol;
N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-hydroxypropyl)-2,2,2-trifluoroacetamide;
tert-butyl (3-(3,6-dibromo-9H-carbazol-9-yl)-2-hydroxypropyl)carbamate;
5-(2-hydroxy-3-phenoxypropyl)-5H-pyrimido[5,4-b]indole-2-carboxylic acid;

N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-hydroxypropyl)acetamide;
ethyl (3-(3,6-dibromo-9H-carbazol-9-yl)-2-hydroxypropyl)carbamate;
6-bromo-9-(3-(4-bromophenoxy)-2-hydroxypropyl)-9H-carbazole-3-carbonitrile;
methyl 9-(2-hydroxy-3-phenoxypropyl)-9H-pyrido[3,4-b]indole-3-carboxylate;
5 N-(3-(3-bromo-6-methyl-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine;
or a salt (e.g., a pharmaceutically acceptable salt) thereof.

In some embodiments, the compound can be those listed in Table 1, in particular those having a $\Delta(\text{Sinf-S0})/\text{AC50}$ value greater than about 0, or greater than about 1, or greater than about 2, or
10 greater than about 3, or greater than about 4, or greater than about 5, or greater than about 10, or
greater than about 20, or greater than about 30, or greater than about 40, or greater than about 50,
or greater than about 60, or greater than about 70, or greater than about 80, or greater than about
90, or greater than about 100.

15 The compounds can be further studied, purified and/or modified. For example, the compounds may
contain one or more asymmetric centers and thus occur as racemates and racemic mixtures,
enantiomerically enriched mixtures, single enantiomers, individual diastereomers and
diastereomeric mixtures. All such isomeric forms of these compounds are expressly included in the
present disclosure. The compounds of the present disclosure may also contain linkages (e.g.,
20 carbon-carbon bonds, carbon-nitrogen bonds such as amide bonds) wherein bond rotation is
restricted about that particular linkage, e.g. restriction resulting from the presence of a ring or
double bond. Accordingly, all *cis/trans* and *E/Z* isomers and rotational isomers are expressly
included in the present disclosure. The compounds of the present disclosure may also be
represented in multiple tautomeric forms, in such instances, the present disclosure expressly
25 includes all tautomeric forms of the compounds described herein, even though only a single
tautomeric form may be represented. All such isomeric forms of such compounds are expressly
included in the present disclosure.

Optical isomers can be obtained in pure form by standard procedures known to those skilled in the art, and include, but are not limited to, diastereomeric salt formation, kinetic resolution, and asymmetric synthesis. See, for example, Jacques, et al., *Enantiomers, Racemates and Resolutions* (Wiley Interscience, New York, 1981); Wilen, S.H., et al., *Tetrahedron* 33:2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, S.H. *Tables of Resolving Agents and Optical Resolutions* p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972), each of which is incorporated herein by reference in their entireties. It is also understood that the present disclosure encompass all possible regioisomers, and mixtures thereof, which can be obtained in pure form by standard separation procedures known to those skilled in the art, and include, but are not limited to, column chromatography, thin-layer chromatography, and high-performance liquid chromatography.

The compounds of the present disclosure include the compounds themselves, as well as their salts and their prodrugs, if applicable. A salt, for example, can be formed between an anion and a positively charged substituent (e.g., amino) on a compound described herein. Suitable anions include chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, and acetate. Likewise, a salt can also be formed between a cation and a negatively charged substituent (e.g., carboxylate) on a compound described herein. Suitable cations include sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation such as tetramethylammonium ion. Examples of prodrugs include C₁₋₆ alkyl esters of carboxylic acid groups, which, upon administration to a subject, are capable of providing active compounds.

Pharmaceutically acceptable salts of the compounds of the present disclosure include those derived from pharmaceutically acceptable inorganic and organic acids and bases. As used herein, the term “pharmaceutically acceptable salt” refers to a salt formed by the addition of a pharmaceutically acceptable acid or base to a compound disclosed herein. As used herein, the phrase “pharmaceutically acceptable” refers to a substance that is acceptable for use in pharmaceutical applications from a toxicological perspective and does not adversely interact with the active ingredient.

Examples of suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycolate, hemisulfate, 5 heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, thiocyanate, tosylate and undecanoate. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the present disclosure and their 10 pharmaceutically acceptable acid addition salts. Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N-(alkyl)₄⁺ salts. The present disclosure also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such 15 quaternization. Salt forms of the compounds of any of the formulae herein can be amino acid salts of carboxyl groups (e.g. L-arginine, -lysine, -histidine salts).

Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418; Journal of Pharmaceutical Science, 66, 2 (1977); and 20 "Pharmaceutical Salts: Properties, Selection, and Use A Handbook; Wermuth, C. G. and Stahl, P. H. (eds.) Verlag Helvetica Chimica Acta, Zurich, 2002 [ISBN 3-906390-26-8] each of which is incorporated herein by reference in their entireties.

The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid 25 and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present disclosure.

In addition to salt forms, the present disclosure provides compounds which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that undergo chemical changes under physiological conditions to provide the compounds of the present disclosure. Additionally, prodrugs can be converted to the compounds of the present disclosure by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present disclosure when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be more bioavailable by oral administration than the parent drug. The prodrug may also have improved solubility in pharmacological compositions over the parent drug. A wide variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug. An example, without limitation, of a prodrug would be a compound of the present disclosure which is administered as an ester (the "prodrug"), but then is metabolically hydrolyzed to the carboxylic acid, the active entity. Additional examples include peptidyl derivatives of a compound of the present disclosure.

The present disclosure also includes various hydrate and solvate forms of the compounds.

The compounds of the present disclosure may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (^3H), iodine-125 (^{125}I) or carbon-14 (^{14}C). All isotopic variations of the compounds of the present disclosure, whether radioactive or not, are intended to be encompassed within the scope of the present disclosure.

Synthesis

The compounds of the present disclosure can be conveniently prepared in accordance with the procedures outlined in the Examples sections of US Patent No. 8,362,277; U.S. Publication No. 2011/0015217; U.S. Publication No. 2012/0022096; U.S. Publication No. 2013/0040977; U.S. Application No. 14/339,772 filed July 24, 2014; U.S. Provisional Patent Application No. 61/902,680

filed November 11, 2013 and U.S. Provisional Patent Application No. 61/912,625 filed December 6, 2013, all of which are hereby incorporated herein by reference in their entirety. The compounds can also be prepared from commercially available starting materials, compounds known in the literature, or readily prepared intermediates, by employing standard synthetic methods and procedures known to those skilled in the art. Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be readily obtained from the relevant scientific literature or from standard textbooks in the field. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures. Those skilled in the art of organic synthesis will recognize that the nature and order of the synthetic steps presented may be varied for the purpose of optimizing the formation of the compounds described herein.

Synthetic chemistry transformations (including protecting group methodologies) useful in synthesizing the compounds described herein are known in the art and include, for example, those such as described in R.C. Larock, *Comprehensive Organic Transformations*, 2d.ed., Wiley-VCH Publishers (1999); P.G.M. Wuts and T.W. Greene, *Protective Groups in Organic Synthesis*, 4th Ed., John Wiley and Sons (2007); L. Fieser and M. Fieser, *Fieser and Fieser's Reagents for Organic Synthesis*, John Wiley and Sons (1994); and L. Paquette, ed., *Encyclopedia of Reagents for Organic Synthesis*, John Wiley and Sons (1995), and subsequent editions thereof.

The processes described herein can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., ^1H or ^{13}C), infrared spectroscopy (FT-IR), spectrophotometry (e.g., UV-visible), or mass spectrometry (MS), or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography (TLC).

Preparation of compounds can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in Greene, et al., *Protective Groups in Organic Synthesis*, 2d. Ed., Wiley & Sons, 1991, which is incorporated herein by reference in its entirety.

The reactions of the processes described herein can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially nonreactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, i.e., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected.

Resolution of racemic mixtures of compounds can be carried out by any of numerous methods known in the art. An example method includes preparation of the Mosher's ester or amide derivative of the corresponding alcohol or amine, respectively. The absolute configuration of the ester or amide is then determined by proton and/or ^{19}F NMR spectroscopy. An example method includes fractional recrystallization using a "chiral resolving acid" which is an optically active, salt-forming organic acid. Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids. Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine). Suitable elution solvent compositions can be determined by one skilled in the art.

Pharmaceutical Compositions

The term "pharmaceutically acceptable carrier" refers to a carrier or adjuvant that may be administered to a subject (e.g., a patient), together with a compound of the present disclosure, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.

5

Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the compositions of the present disclosure include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d- α -tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as

10 Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts, or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, 15 sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. Cyclodextrins such as α -, β -, and γ -cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl- β -cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein.

20

The compositions for administration can take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, the compositions are presented in unit dosage forms to facilitate accurate dosing. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined 25 quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Typical unit dosage forms include prefilled, premeasured ampules or syringes of the liquid compositions or pills, tablets, capsules, lozenges or the like in the case of solid compositions. In such compositions, the compound is usually a minor component (from about 0.1 to about 50% by weight or preferably from about 1 to about 40% by weight) with the

remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.

The amount administered depends on the compound formulation, route of administration, etc. and is generally empirically determined in routine trials, and variations will necessarily occur depending on the target, the host, and the route of administration, etc. Generally, the quantity of active compound in a unit dose of preparation may be varied or adjusted from about 1, 3, 10 or 30 to about 30, 100, 300 or 1000 mg, according to the particular application. In a particular embodiment, unit dosage forms are packaged in a multipack adapted for sequential use, such as blisterpack, comprising sheets of at least 6, 9 or 12 unit dosage forms. The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small amounts until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.

The following are examples (Formulations 1-4) of capsule formulations.

Capsule Formulations

Capsule Formulation	Formulation 1 mg/capsule	Formulation 2 mg/capsule	Formulation 3 mg/capsule	Formulation 4 mg/capsule
Compound (solid solution)	100	400	400	200
Silicon Dioxide	0.625	2.5	3.75	1.875
Magnesium Stearate NF2	0.125	0.5	0.125	0.625
Croscarmellose Sodium NF	11.000	44.0	40.0	20.0
Pluronic F68 NF	6.250	25.0	50.0	25.0
Silicon Dioxide NF	0.625	2.5	3.75	1.875
Magnesium Stearate NF	0.125	0.5	1.25	0.625

Total	118.750	475.00	475.00	475.00
Capsule Size	No.4	No.0	No.0	No.2

Preparation of Solid Solution

Crystalline compound (80 g/batch) and the povidone (NF K29/32 at 160 g/batch) are dissolved in methylene chloride (5000 mL). The solution is dried using a suitable solvent spray dryer and the residue reduced to fine particles by grinding. The powder is then passed through a 30 mesh screen and confirmed to be amorphous by x-ray analysis.

The solid solution, silicon dioxide and magnesium stearate are mixed in a suitable mixer for 10 minutes. The mixture is compacted using a suitable roller compactor and milled using a suitable mill fitted with 30 mesh screen. Croscarmellose sodium, Pluronic F68 and silicon dioxide are added to the milled mixture and mixed further for 10 minutes. A premix is made with magnesium stearate and equal portions of the mixture. The premix is added to the remainder of the mixture, mixed for 5 minutes and the mixture encapsulated in hard shell gelatin capsule shells.

Use

The compounds disclosed herein can be used, in one aspect, to treat DNA-damaging agent (e.g., anthracycline) mediated cardiotoxicity. The compounds can also be used to treat one or more diseases, disorders, or conditions caused by, or associated with, aberrant (e.g., insufficient) neurogenesis or accelerated neuron cell death in a subject in need thereof.

In one aspect, methods for treating (e.g., controlling, relieving, ameliorating, alleviating, or slowing the progression of) or methods for preventing (e.g., delaying the onset of or reducing the risk of developing) one or more diseases, disorders, or conditions. The methods include administering to the subject an effective amount of a compound of formula (I) (and/or any other compound described herein) or a salt (e.g., a pharmaceutically acceptable salt) thereof as defined anywhere herein to the subject.

In another aspect, the use of a compound of formula (I) (and/or any other compound described herein) or a salt (e.g., a pharmaceutically acceptable salt) thereof as defined anywhere herein in the preparation of, or for use as, a medicament for the treatment (e.g., controlling, relieving, ameliorating, alleviating, or slowing the progression of) or prevention (e.g., delaying the onset of or
5 reducing the risk of developing) of one or more diseases, disorders, or conditions.

In embodiments, the one or more diseases, disorders, or conditions can include DNA-damaging agent (e.g., anthracycline) mediated cardiotoxicity, neuropathies, nerve trauma, and neurodegenerative diseases. In embodiments, the one or more diseases, disorders, or conditions
10 can be diseases, disorders, or conditions caused by, or associated with aberrant (e.g., insufficient) neurogenesis (e.g., aberrant hippocampal neurogenesis as is believed to occur in neuropsychiatric diseases) or accelerated death of existing neurons. Examples of the diseases, disorders, or conditions include, but are not limited to, DNA-damaging agent (e.g., anthracycline) mediated cardiotoxicity, schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic
15 brain injury and/or a visual symptom associated therewith, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, cognitive decline and/or general frailty associated with
20 normal aging and/or chemotherapy, chemotherapy induced neuropathy, concussive injury, crush injury, peripheral neuropathy, diabetic neuropathy, post-traumatic headache, multiple sclerosis, retinal degeneration and dystrophy (such as Leber congenital amaurosis, retinitis pigmentosa, cone-rod dystrophy, microphthalmia, anophthalmia, myopia, and hyperopia), spinal cord injury, traumatic spinal cord injury, peripheral nerve injury (such as peripheral nerve crush injury, neonatal brachial plexus palsy, and traumatic facial nerve palsy), retinal neuronal death related diseases (such as
25 glaucoma and age related macular degeneration, diabetic retinopathy, retinal blood vessel occlusions, retinal medication toxicity (such as what amino glycosides or plaquenil can cause), retinal trauma (e.g., post-surgical), retinal infections, choroidal dystrophies, retinal pigmentary retinopathies, inflammatory and cancer mediated auto immune diseases that result in retinal

- neuronal cell death), Autism, Stargardt disease, Kearns-Sayre syndrome, Pure neurosensory deafness, Hereditary hearing loss with retinal diseases, Hereditary hearing loss with system atrophies of the nervous system, Progressive spinal muscular atrophy, Progressive bulbar palsy, Primary lateral sclerosis, Hereditary forms of progressive muscular atrophy and spastic paraplegia,
- 5 Frontotemporal dementia, Dementia with Lewy bodies, Corticobasal degeneration, Progressive supranuclear palsy, Prion disorders causing neurodegeneration, Multiple system atrophy (olivopontocerebellar atrophy), Hereditary spastic paraparesis, Friedreich ataxia, Non-Friedreich ataxia, Spinocerebellar atrophies, Amyloidoses, Metabolic-related (e.g., Diabetes) neurodegenerative disorders, Toxin-related neurodegenerative disorders, Multiple sclerosis,
- 10 Charcot Marie Tooth, Diabetic neuropathy, Metabolic neuropathies, Endocrine neuropathies, Orthostatic hypotension, Creutzfeldt-Jacob Disease, Primary progressive aphasia, Frontotemporal Lobar Degeneration, Cortical blindness, Shy-Drager Syndrome (Multiple, System Atrophy with Orthostatic Hypotension), Diffuse cerebral cortical atrophy of non-Alzheimer type, Lewy-body dementia, Pick disease (lobar atrophy), Thalamic degeneration, Mesolimbocortical dementia of non-
- 15 Alzheimer type, Nonhuntingtonian types of chorea and dementia, Cortical-striatal-spinal degeneration, Dementia-Parkinson-amyotrophic lateral sclerosis complex, Cerebrocerebellar degeneration, Cortico-basal ganglionic degeneration, Familial dementia with spastic paraparesis or myoclonus, and Tourette syndrome.
- 20 The resultant promotion of neurogenesis or survival of existing neurons (i.e., a resultant promotion of survival, growth, development, function and/or generation of neurons) may be detected directly, indirectly or inferentially from an improvement in, or an amelioration of one or more symptoms of the disease or disorder caused by or associated with aberrant neurogenesis or survival of existing neurons. Suitable assays which directly or indirectly detect neural survival, growth, development,
- 25 function and/or generation are known in the art, including axon regeneration in rat models (e.g. Park et al., Science. 2008 Nov 7; 322:963-6), nerve regeneration in a rabbit facial nerve injury models (e.g. Zhang et al., J Transl Med. 2008 Nov 5;6(1):67); sciatic nerve regeneration in rat models (e.g. Sun et al., Cell Mol Neurobiol. 2008 Nov 6); protection against motor neuron degeneration in mice (e.g. Poesen et al., J. Neurosci. 2008 Oct 15;28(42):10451-9); rat model of Alzheimer's disease,

(e.g. Xuan et al., *Neurosci Lett.* 2008 Aug 8;440(3):331-5); animal models of depression (e.g. Schmidt et al., *Behav Pharmacol.* 2007 Sep;18(5-6):391-418; Krishnan et al., *Nature* 2008, 455, 894-902); and/or those exemplified herein.

5 Administration

The compounds and compositions described herein can, for example, be administered orally, parenterally (e.g., subcutaneously, intracutaneously, intravenously, intramuscularly, intraarticularly, intraarterially, intrasynovially, intrasternally, intrathecally, intralesionally and by intracranial injection or infusion techniques), by inhalation spray, topically, rectally, nasally, buccally, vaginally, 10 via an implanted reservoir, by injection, subdermally, intraperitoneally, transmucosally, or in an ophthalmic preparation, with a dosage ranging from about 0.01 mg/kg to about 1000 mg/kg, (e.g., from about 0.01 to about 100 mg/kg, from about 0.1 to about 100 mg/kg, from about 1 to about 100 mg/kg, from about 1 to about 10 mg/kg) every 4 to 120 hours, or according to the requirements of the particular drug. The interrelationship of dosages for animals and humans (based on 15 milligrams per meter squared of body surface) is described by Freireich et al., *Cancer Chemother. Rep.* 50, 219 (1966). Body surface area may be approximately determined from height and weight of the patient. See, e.g., *Scientific Tables*, Geigy Pharmaceuticals, Ardsley, New York, 537 (1970). In certain embodiments, the compositions are administered by oral administration or administration by injection. The methods herein contemplate administration of an effective amount of compound 20 or compound composition to achieve the desired or stated effect. Typically, the pharmaceutical compositions of the present disclosure will be administered from about 1 to about 6 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy.

25 Lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease,

condition or symptoms, the patient's disposition to the disease, condition or symptoms, and the judgment of the treating physician.

Upon improvement of a patient's condition, a maintenance dose of a compound, composition or combination of the present disclosure may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.

In some embodiments, the compounds described herein can be coadministered with one or more other therapeutic agents. In certain embodiments, the additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of the present disclosure (e.g., sequentially, e.g., on different overlapping schedules with the administration of one or more compounds of formula (I) (including any subgenera or specific compounds thereof)). In other embodiments, these agents may be part of a single dosage form, mixed together with the compounds of the present disclosure in a single composition. In still another embodiment, these agents can be given as a separate dose that is administered at about the same time that one or more compounds of formula (I) (including any subgenera or specific compounds thereof) are administered (e.g., simultaneously with the administration of one or more compounds of formula (I) (including any subgenera or specific compounds thereof)). When the compositions of the present disclosure include a combination of a compound of the formulae described herein and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent can be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen.

The compositions of the present disclosure may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the

formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form.

5 The compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are
10 mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated
15 versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms such as emulsions and or suspensions. Other commonly used surfactants such as Tweens or Spans and/or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically
20 acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.

The compositions of the present disclosure may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions. In the case of tablets for oral use, carriers which are commonly used
25 include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions and/or emulsions are administered orally, the active ingredient may be suspended or dissolved in an oily phase is combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.

The compositions of the present disclosure may also be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing a compound of the present disclosure with a suitable non-irritating excipient which is solid at room temperature but
5 liquid at the rectal temperature and therefore will melt in the rectum to release the active components. Such materials include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.

Topical administration of the compositions of the present disclosure is useful when the desired
10 treatment involves areas or organs readily accessible by topical application. For application topically to the skin, the composition should be formulated with a suitable ointment containing the active components suspended or dissolved in a carrier. Carriers for topical administration of the compounds of the present disclosure include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax
15 and water. Alternatively, the composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier with suitable emulsifying agents. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetaryl alcohol, 2-octyldodecanol, benzyl alcohol and water. The compositions of the present disclosure may also be topically applied to the lower intestinal tract by
20 rectal suppository formulation or in a suitable enema formulation.

In some embodiments, topical administration of the compounds and compositions described herein may be presented in the form of an aerosol, a semi-solid pharmaceutical composition, a powder, or a solution. By the term "a semi-solid composition" is meant an ointment, cream, salve, jelly, or
25 other pharmaceutical composition of substantially similar consistency suitable for application to the skin. Examples of semi-solid compositions are given in Chapter 17 of The Theory and Practice of Industrial Pharmacy, Lachman, Lieberman and Kanig, published by Lea and Febiger (1970) and in Remington's Pharmaceutical Sciences, 21st Edition (2005) published by Mack Publishing Company, which is incorporated herein by reference in its entirety.

Topically-transdermal patches are also included in the present disclosure. Also within the present disclosure is a patch to deliver active chemotherapeutic combinations herein. A patch includes a material layer (e.g., polymeric, cloth, gauze, bandage) and the compound of the formulae herein as delineated herein. One side of the material layer can have a protective layer adhered to it to resist passage of the compounds or compositions. The patch can additionally include an adhesive to hold the patch in place on a subject. An adhesive is a composition, including those of either natural or synthetic origin, that when contacted with the skin of a subject, temporarily adheres to the skin. It can be water resistant. The adhesive can be placed on the patch to hold it in contact with the skin of the subject for an extended period of time. The adhesive can be made of a tackiness, or adhesive strength, such that it holds the device in place subject to incidental contact, however, upon an affirmative act (e.g., ripping, peeling, or other intentional removal) the adhesive gives way to the external pressure placed on the device or the adhesive itself, and allows for breaking of the adhesion contact. The adhesive can be pressure sensitive, that is, it can allow for positioning of the adhesive (and the device to be adhered to the skin) against the skin by the application of pressure (e.g., pushing, rubbing,) on the adhesive or device.

The compositions of the present disclosure may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.

A composition having the compound of the formulae herein and an additional agent (e.g., a therapeutic agent) can be administered using any of the routes of administration described herein. In some embodiments, a composition having the compound of the formulae herein and an additional agent (e.g., a therapeutic agent) can be administered using an implantable device. Implantable devices and related technology are known in the art and are useful as delivery systems where a continuous or timed-release delivery of compounds or compositions delineated herein is

desired. Additionally, the implantable device delivery system is useful for targeting specific points of compound or composition delivery (e.g., localized sites, organs). Negrin et al., Biomaterials, 22(6):563 (2001). Timed-release technology involving alternate delivery methods can also be used in the present disclosure. For example, timed-release formulations based on polymer technologies, sustained-release techniques and encapsulation techniques (e.g., polymeric, liposomal) can also be used for delivery of the compounds and compositions delineated herein.

The present disclosure will be further described in the following examples. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting the present disclosure in any manner.

EXAMPLES

Active members of the "pool seven compound three" (P7C3) class of aminopropyl carbazole chemicals foster the survival of neurons in a variety of rodent models of neurodegeneration or nerve cell injury. A P7C3 derivative modified to contain a benzophenone moiety facilitated UV light-mediated cross linking to nicotinamide phosphoribosyltransferase (NAMPT), the rate limiting enzyme involved in the conversion of nicotinamide into nicotinamide adenine dinucleotide (NAD). Administration of active variants of this class of chemicals to cells treated with doxorubicin led to a rebound in intracellular levels of NAD and concomitant protection from doxorubicin-mediated toxicity. Active P7C3 variants likewise enhanced the activity of the purified NAMPT enzyme. Optimized aminopropyl carbazole chemicals offer promise for the development of therapeutics for the treatment of neurodegenerative diseases and other conditions involving nerve cell injury.

BACKGROUND

No substantive therapeutics are available for the treatment of almost any form of disease entailing nerve cell death. Patients suffering from any of a wide spectrum of neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, fronto-temporal dementia and Huntington's disease are condemned to progressive demise of the CNS by virtue of nerve cell death. It is likewise the case that no effective treatments exist for injuries to the brain or

peripheral nervous system, including traumatic or concussive brain injury, spinal cord injury, or peripheral nerve injury. Any chemical having the capacity to safely impede nerve cell death in the context of these varied diseases or injuries would offer the opportunity for transformative impact in modern medicine.

5

Previously we performed a target-agnostic, in vivo screen in search of chemicals that might enhance hippocampal neurogenesis in adult mice (Pieper et al., 2010). The screen was simple in concept. With help from chemists in the Department of Biochemistry at UTSWMC, we selected 1,000 drug-like chemicals from the 250,000 compounds in our high throughput screening center. The
10 compounds were selected to preserve representative chemical diversity of the entire library. They were further selected to enhance the representation of chiral molecules, and to avoid untoward chemical properties such as reactive moieties. The 1,000 molecules were randomly pooled into groups of ten, and each pool was administered directly into the left ventricle of two adult mice. Intracranial delivery was facilitated by stereotactic positioning of a canula fed directly by an Alzet
15 mini-pump containing the mixture of ten chemicals. The drug mixture was administered over a week-long period at concentrations anticipated to deliver mid-nanomolar levels of the ten test compounds. Daily injections of the thymidine analog, bromodeoxyuridine (BrdU), were co-administered in order to monitor the formation of new hippocampal nerve cells. Following compound administration, animals were sacrificed such that brain tissue could be recovered,
20 sectioned and stained with antibodies to BrdU. This two-year screen led to the discovery of a handful of pools that enhanced neurogenesis in both test mice that had been exposed to the pool. Breakdown of the active pools allowed the individual testing of each of the ten chemicals in the pool, leading to the discovery of eight pro-neurogenic chemicals (Pieper et al., 2010).

20

25 Among the eight, pro-neurogenic chemicals, pharmacological testing gave evidence that only one of the compounds had favorable pharmacological properties. Pool seven (P7) contained an aminopropyl carbazole as its active, third compound (C3). When administered to mice via intraperitoneal (IP), intravenous (IV) or oral routes, the P7C3 compound revealed favorable half-life, volume of distribution and brain penetration. It was also found that P7C3 could be safely

administered to mice and rats for prolonged periods at concentrations well above those required to stimulate hippocampal neurogenesis, giving evidence that the molecule was not overtly toxic to rodents.

5 Although it was initially anticipated that pro-neurogenic compounds would act by stimulating the mitotic birth of newborn nerve cells in the subgranular layer of the dentate gyrus, P7C3 revealed no such activity. The two-fold enhanced level of BrdU-positive neurons observed over a week-long dose of P7C3 was absent when animals were pulsed with BrdU for only 24 hours. More strikingly, when BrdU was pulsed for only one day, and animals were subsequently administered P7C3 for a
10 month, we observed a far larger enhancement in BrdU-positive hippocampal neurons (500%). Instead of stimulating the mitotic division of neuronal stem cells, these observations gave evidence that P7C3 mitigated the death of newborn neurons. Under the conditions of our study only 10-20% of newborn neurons survive the month-long differentiation process to become properly wired hippocampal neurons. Prolonged administration of P7C3 significantly mitigated the death of
15 newborn neurons, such that upwards of half of the cells survive the month-long “differentiation gauntlet” taking place between stem cell mitosis and terminal nerve cell differentiation. Indeed, localized expression of pro-apoptotic proteins in newborn neurons has been found to limit neurogenesis, whereas expression of anti-apoptotic proteins enhances neurogenesis in adult mice (Kim et al., 2009) (Kuhn et al., 2005) (Sun et al., 2004). It has likewise been found that the pro-
20 neurogenic benefits of wheel running and/or enriched environment for caged rodents is primarily attributable to neuroprotective effects on newborn hippocampal neurons (Kempermann et al., 1997; Kim et al., 2010) (van Praag et al., 1999).

Having discovered the aminopropyl carbazole chemical in an unbiased, in vivo screen, and having
25 found that it protects newborn neurons from death, we use methods of medicinal chemistry to improve the potency and pharmacological properties of P7C3 (MacMillan et al., 2011; Naidoo et al., 2014; Pieper et al., 2014). Using these improved, active derivatives of P7C3 we have observed neuroprotective activity in animal models of Parkinson’s disease (De Jesus-Cortes et al., 2012), amyotrophic lateral sclerosis (Tesla et al., 2012), as well as concussive injury to the rodent brain

(accompanying manuscript). Of significant concern, however, was the fact that the mechanism of action of the P7C3 class of neuroprotective chemicals remained unknown. Here we provide evidence that these chemicals function by enhancing the activity of the rate-limiting enzyme in the salvage of nicotinamide adenine dinucleotide (NAD) from nicotinamide.

5

RESULTS

Active variants of P7C3 protect cultured cells from doxorubicin-mediated toxicity

Progress on studies aimed towards resolving the mode of action of P7C3 has been hampered by the fact that we have been limited to studies of drug action in living animals. Our standard assay of neurogenesis requires, under optimal conditions, a one month turn-around from the synthesis of a new derivative to a score for its neuroprotective activity. In efforts to break this logjam, we tested whether P7C3 might have cell-protective activity to any of eight generic toxins. The active A20 variant of P7C3 was found to protect cultured U2OS cells from doxorubicin-mediated toxicity (FIG. 1A). By contrast, no evidence of drug-mediated protection was observed for any of seven other toxins (FIG. 8). Furthermore, as judged by the DNA damage marker – phosphorylation of H2AX, and the hallmark of apoptosis – caspase-3 activation, co-administration of A20 blocked doxorubicin-induced apoptosis, but not DNA damage response (FIG. 9).

In order to assess whether a correlation might exist between pro-neurogenic activity in living mice and doxorubicin toxicity (dox:tox) protection, we assayed 224 compounds that have been synthesized and assayed for pro-neurogenic activity over the past 4-5 years (Table 1). These include hundreds of structure:activity relationship (SAR) derivatives of P7C3, as well as a number of tricyclic antidepressants reported in the literature to have pro-neurogenic activity (Malberg et al., 2000). P7C3 derivatives were the only molecules having dox:tox protective activity (FIG. 10). Further inspection of the data revealed that the chemical features of the carbazole ring, length of the aliphatic linker, and nature of the aromatic ring were all important determinants for both pro-neurogenic activity and dox:tox protection. Perhaps most compellingly, it was observed that the (-)-P7C3-S243 enantiomer that was active in the in vivo neurogenesis assay (Naidoo et al., 2014), the MPTP model of Parkinson's disease (Naidoo et al., 2014), and the concussive blast injury model (co-

20

25

submitted manuscript) was also protective in the dox:tox assay (FIG. 1B). By contrast, the (+)-P7C3-S243 enantiomer that was far less active in the three in vivo assays of neuroprotection was also considerably less active in the dox:tox protection assay. From these observations we conclude that active derivatives of P7C3 function by a related mechanism to protect neurons in living animals as well as cultured U2OS cells exposed to doxorubicin.

Identification of p70 and p55 as intracellular targets of P7C3

Various methods have been employed in efforts to identify the intracellular target of P7C3, including biotinylation followed by affinity purification, radiolabeling followed by filter binding assays, and photo-crosslinking. Among these strategies, the photo-crosslinking approach has been uniquely successful. P7C3-S326 was prepared to contain both a benzophenone for photo-crosslinking and an alkyne moiety for use in click chemistry (FIG. 2A). This derivative was found to be active in both the in vivo neurogenesis assay and the dox:tox assay. When incubated with cultured cells, exposed to UV light, subjected to click chemistry-mediated addition of a fluorescent dye, then resolved on SDS polyacrylamide gels, the P7C3-S326 derivative became covalently attached to roughly a dozen proteins. Among the covalently modified proteins, only one could be competed when the cells were co-incubated with a 30X excess of the active A20 variant of P7C3. This polypeptide exhibited an apparent molecular mass of 70kD (FIG. 2B).

Binding competition assays were conducted with 168 chemical derivatives of P7C3 as a means of testing whether there might be a correlation between dox:tox protection and binding competition. Cultured cells were co-exposed to P7C3-S326 (0.3uM) and the individual P7C3 variants (5uM), exposed to UV light, lysed, clicked to a fluorescent dye and run on SDS gels (FIG. 11). The scatter plot shown in FIG. 2D revealed a statistically significant correlation between the two activities, yielding a P value of 9.4×10^{-20} . It can thus be predicted with a high level of confidence that active variants of P7C3 are able to compete for P7C3-S326 crosslinking, but that inactive variants cannot. Armed with this knowledge, cell fractionation experiments were performed in order to enrich for the p70 band. During the course of these studies it was periodically observed that P7C3-S326 could also be crosslinked to a second band running with an apparent molecular weight of 55kD. Just as

was the case for p70, active variants of P7C3 competed for p55 binding, whereas inactive variants did not. Moreover, both proteins co-purified with a cellular fraction following centrifugation at 12,000G.

5 **The p70 and p55 targets of P7C3 correspond to NAMPT**

Partially purified protein preparations were resolved by 2D gel electrophoresis. In order to discriminate between protein spots competed by an excess of the active, A20 variant of P7C3, and those that were not, separate lysates were prepared from cells that had been co-exposed to the P7C3-A20 competitor or not. Click chemistry was used to append a red fluorescent dye onto P7C3-
10 S326-modified proteins of the former lysates (Kolb et al., 2001). The latter lysates were modified by a green dye, such that in imaging 2D gels, we could focus on green protein spots and avoid spots labeled by both green and red dyes. Such efforts led to the identification of green-only spots migrating at either 70kD or 55kD (FIGS. 3A-3C). Proteins of both molecular weights migrated in the isoelectric focusing dimension at four closely spaced pH positions. This electrophoretic behavior
15 might be consistent with post-translational modifications of the same protein, leading to different isoforms bearing slight differences in ionic charge. Perplexingly, the pattern of charge distribution was identical for the 70kD and 55kD polypeptides.

The eight green-only spots, four from p70 and four from p55, were picked and subjected to shotgun
20 mass spectrometry for protein identification. All four of the p55 spots yielded by far the highest number of spectral counts for nicotinamide phosphoribosyltransferase (NAMPT) (Table 2). Both the predicted size (55kD) and isoelectric point (pH 6.7) of NAMPT match spots 1-4 picked from the 2D gel. Likewise, mass spectrometry based analysis gave substantive percentage coverage levels of 12%, 82%, 38% and 62% for the NAMPT enzyme in spots 1-4 (Table 2). By contrast, no proteins
25 could be identified above the false discovery rate for the four p70 spots. Post-staining of the 2D gel with spiro ruby dye showed prominent protein staining for all four of the p55 spots, and no staining for any of the four p70 spots (FIG. 3D). Apparently, despite equivalent photo-crosslinking by P7C3-S326, the molar ratio of drug modification of p70 must be at least three orders of magnitude greater than p55.

The perplexing relationship between p70 and p55 was clarified upon adding 7M urea to the SDS PAGE gels used to resolve the two bands. In the absence of urea, almost all of the P7C3-S326-modified material migrated as the p70 band. Addition of urea to the gel converted all of the labeled material to the p55 band (FIG. 4A). By running a gel crafted to contain a horizontal gradient of urea, 7M on the right and no urea on the left, it was possible to observe graded conversion of p70 into p55 (FIG. 4B). These observations give evidence that when NAMPT is covalently bound by P7C3-S326, it can adopt an anomalous pattern of electrophoretic migration under gel conditions that are not fully denaturing.

Active derivatives of P7C3 restore NAD levels in doxorubicin-treated cells

Having observed P7C3-S326 crosslinking to both the p70 and p55 forms of NAMPT, we wondered whether active variants of P7C3 might modify the activity of the enzyme. The NAMPT enzyme controls the rate limiting step in the NAD salvage pathway (Preiss and Handler, 1958). NAMPT is an obligate dimer whose molecular structure has been resolved by X-ray crystallography (Khan et al., 2006) (Wang et al., 2006). On the basis of molar ratio of crosslinking, P7C3-S326 strongly prefers the p70 isoform of NAMPT relative to the p55 isoform. Hypothesizing that p70 represents a drug-altered form of NAMPT, we tested whether highly active P7C3-A20 variant might either enhance or reduce NAD levels in living cells.

Doxorubicin is a DNA-damaging toxin known to activate the poly ADP-ribose polymerase (PARP) enzyme as a central feature of DNA repair (Pacher et al., 2002) (Munoz-Gamez et al., 2009). PARP uses NAD as the donor for poly ADP-ribose synthesis and hence lowers cellular levels of NAD. U2OS cells exposed to sub-lethal levels of doxorubicin were lysed in methanol, cleared by centrifugation and subjected to metabolite analysis by mass spectrometry. These methods allow for the simultaneous, quantitative analysis of hundreds of intracellular metabolites (Tu et al., 2007) (Wang et al., 2009). As expected, doxorubicin treatment led to a significant decline in NAD levels relative to all other metabolites assayed. Co-administration of the A20 variant of P7C3 led to a dose-dependent replenishment of NAD (Fig 5A). The mass spectrometry methods used to quantitate

metabolite levels measured NAD relative to hundreds of other intracellular metabolites. As such, the ability of the A20 variant of P7C3 to restore intracellular levels of NAD does not simply reflect the generalized health of cells, but instead reflects the relative increase in NAD levels compared with hundreds of other metabolites.

5

A more facile method of quantifying the NAD analyte, employing the commercially available "NAD/NADH-Glo" kit (Promega), confirmed P7C3-A20-mediated rebound of NAD levels in doxorubicin-treated U2OS cells. We also observed NAD rebound for the racemic mix of the active P7C3-S243 compound, but no rebound at all for the inactive P7C3-S6 and P7C3-S117 compound
10 variants (Fig 5B). This method of assay was used to test 159 variants of P7C3 that had been used to query the correlative relationship between dox:tox protection and competition in the P7C3-S326 crosslinking assay (Table 1 and FIG. 2D). Each chemical variant of P7C3 was co-incubated with doxorubicin on cultured U2OS cells at five doses (0.03uM, 0.1uM, 0.3uM, 1uM and 3uM). After 45hrs incubation, cells were assayed for intracellular levels of NAD (FIG. 12). The scatter plot shown
15 in FIG. 5C reveals exceptional concordance between the dox:tox protective activities of the 159 compounds and their relative abilities to enhance NAD levels (correlative P value of 1.8×10^{-35}).

NAMPT is the rate limiting enzyme in the salvage pathway whereby cells sequentially convert nicotinamide into nicotinamide adenine mononucleotide (NMN) and NAD (Preiss and Handler,
20 1958). If active variants of P7C3 indeed bind to the NAMPT dimer in a manner fostering its activity, then these compounds should enhance the flux of nicotinamide through the salvage pathway. To test this hypothesis, ^{14}C -labeled nicotinamide was administered to cultured U2OS cells. Six hours later, cells were lysed in perchloric acid and cleared by centrifugation so that soluble materials could be separated by thin layer chromatography (TLC) followed by autoradiography. As shown in FIG. 6,
25 enhanced conversion of radiolabeled nicotinamide into NMN and NAD was observed in a dose-responsive manner upon exposure of cultured U2OS cells to the active, A20 variant of P7C3.

Active variants of P7C3 enhance the activity of the purified NAMPT enzyme

A recombinant form of the human NAMPT enzyme was cloned, expressed and purified according to

published conditions (Khan et al., 2006) (Wang et al., 2006). The enzymatic activity of recombinant NAMPT was monitored in a coupled assay wherein nicotinamide conversion to NMN was followed by sequential production of NAD (via the NMNAT enzyme) and NADH (via alcohol dehydrogenase). To minimize variation, a control reaction was run in each assay prior to compound addition. As shown in FIG. 7A, the A20 variant of P7C3 activated the enzyme reaction in a dose dependent manner. No activation of NADH production was observed when NAMPT was eliminated from the reaction, giving evidence that enhancement did not result from compound effects on either NMNAT or alcohol dehydrogenase.

Two additional experiments were conducted to investigate activation of the recombinant NAMPT enzyme. First, thirty derivatives of P7C3 having varied activity were tested for enzyme activation. The ability of the thirty variants to activate NAMPT in the coupled enzyme assay was then correlated on scatter plots to three other measures of compound activity: (i) ability to protect cultured cells from doxorubicin toxicity; (ii) ability to compete with photo cross-linking by P7C3-S326 in living cells; and (iii) ability to restore NAD levels in doxorubicin treated cells (FIG. 7B). In all cases statistically significant evidence of correlation was observed. Second, we compared the activities of the racemic mix of P7C3-S243, the (-)P7C3-S243 enantiomer and the (+)P7C3-S243 enantiomer in NAMPT enzyme assay. As shown in FIG. 7C, the (-)P7C3-S243 enantiomer was more active in stimulating NAMPT than the racemic mix, which – in turn – was more active than the (+)P7C3-S243 enantiomer. This same hierarchy of activity has been observed in all in vivo assays tested to date, including adult neurogenesis, and the MPTP model of Parkinson's disease (Naidoo et al., 2014), concussive blast injury (accompanying manuscript), protection of cultured cells from doxorubicin-mediated activity (FIG. 1) and rebound of NAD levels in doxorubicin-treated cells (FIG. 11).

DISCUSSION

Why is it that active variants of P7C3 were able to protect cultured cells from doxorubicin-mediated toxicity, in the face of no protective activity against seven other toxins? Three observations can now be seen to help understand this selectivity. First, doxorubicin reduces intracellular levels of NAD, likely via activation of poly-ADP ribose polymerase (PARP). Second, active variants of P7C3 protect

cultured cells from dox:tox, likely by stimulating a rebound in the intracellular levels of NAD. Third, active variants of P7C3 enhance the activity of the purified, recombinant NAMPT enzyme. We conclude that the dox:tox protective activity of our aminopropyl carbazole chemicals is directly reflective of their ability to enhance the salvage pathway whereby nicotinamide is converted to NAD.

The target-agnostic in vivo screen performed years ago led, in an unbiased manner, to the P7C3 class of neuroprotective chemicals (Pieper et al., 2010). We now hypothesize that the neuroprotective efficacy of our aminopropyl carbazole chemicals can be attributed to their ability to foster salvage of NAD from nicotinamide. This interpretation is concordant with an equally unbiased series of forward genetic studies performed over the past three decades. In the 1980's scientists working in Oxford, England described a variant strain of mice that impedes Wallerian degeneration, designated the Wallerian degeneration slow (*wlds*) strain (Lunn et al., 1989). In simple terms, Wallerian degeneration can be described as the demise of axonal processes distal from the cell body to a site of nerve crush. Axons of *wlds* mice survive a nerve crush far longer than those of wild type mice. The *wlds* gene was positionally cloned in the 1990's and found to exist as a triplicated fusion gene encoding the first 70 amino acids of Ufd2a, a ubiquitin-chain assembly factor, linked directly to the complete coding sequence of nicotinamide mononucleotide adenylyl-transferase 1 (NMNAT1) (Coleman et al., 1998) (Conforti et al., 2000) (Mack et al., 2001). Whereas NAMPT initiates salvage from nicotinamide, NMNAT1 is one of three enzymes that convert the NMN product into NAD. In a beautiful paper published in 2004 in Science, Dr. Jeff Milbrandt and colleagues provided compelling evidence that the *wlds* phenotype can be attributed primarily to the over-expression of NMNAT1 (Araki et al., 2004). The closing sentence of their manuscript is unusually prescient, reading – "It is possible that the alteration of NAD levels by manipulation of the NAD biosynthetic pathway, Sir2 protein activity, or other downstream effectors will provide new therapeutic opportunities for the treatment of diseases involving axonopathy and neurodegeneration." We offer the conclusion that this is exactly what active variants of the P7C3 category of neuroprotective drugs do – they enhance the intracellular production of NAD by agonizing the activity of the rate limiting enzyme in the NAD salvage pathway.

It has recently been reported that NAD production attenuates as a function of aging in the hippocampus of rodents (Stein and Imai, 2014). This study further reported age-related decline in the expression of NAMPT in the hippocampus, along with evidence that selective elimination of the NAMPT gene in neuronal stem cells significantly impairs hippocampal neurogenesis. Now that we understand that active members of the P7C3 class of compounds function by enhancing the activity of the NAMPT enzyme, the observations of Stein and Imai lend credibility to our original discovery of P7C3 as a chemical stimulant of hippocampal neurogenesis.

In addition to offering progress towards an understanding of the mode of action of the P7C3 class of neuroprotective chemicals, this work also points to a number of important, unanswered questions. First and foremost, where on the NAMPT enzyme do our chemicals bind, and how do they facilitate agonistic activation? Second, why is it that covalent binding of S326 causes NAMPT to migrate in an anomalous manner in SDS PAGE gels? Third, is it indeed the case that NAD levels may be compromised as a function of nerve cell injury or neuronal dysfunction as a consequence of neurodegenerative disease? Fourth, might NAMPT be regulated in vivo by an endogenous metabolite that is either mimicked or counteracted by active variants of the P7C3 class of neuroprotective chemicals?

We close with two observations that may or may not be related. Studies of aged mice have led to the reported decline in tissue NAD levels, and that certain aspects of age-related decline in overall health can be reversed by nutritional supplementation of NMN (Gomes et al., 2013). In our initial studies of P7C3 we reported compound-mediated abrogation of cognitive decline in aged Fisher rats (Pieper et al., 2010). Included in such studies was the unanticipated observation that compound treated rats maintained body weight relative to the frailty of vehicle-treated controls. These distinct studies offer the possibility of considering the P7C3 class of neuroprotective chemicals as potential treatments for generalized frailty typical of aged animals and humans.

EXPERIMENTAL PROCEDURES

Cell culture

Osteosarcoma U2OS cells were grown in DMEM medium (Sigma) supplemented with 10% FBS. Lung cancer H2122 cells were cultured in RPMI-1640 medium (HyClone) supplemented with 5% FBS. These adherent cell lines were cultured employing standard procedures.


5

Cell survival assay

Cell survival assay was performed in 96-well plates using CellTiter-Glo Luminescent Cell Viability Assay kit (Promega) that measures cellular ATP content. The CellTiter-Glo reagent was diluted by adding 2 volumes of PBS containing 1% Triton X-100. 50 μ l of diluted reagent was directly added to 100 μ l of cell culture medium per well. Plates were incubated at room temperature for 10 minutes. Luminescence was recorded by Tecan SPECTRAFluor Plus reader (Tecan). Cell survival was presented as the percentage of viable cells compared with untreated control, and mean $\pm$ SD was calculated from duplicates. The dox:tox assay of P7C3 analogs was carried out in the HTS Core (University of Texas Southwestern Medical Center) using the EnVision multimode plate reader (Perkin Elmer).

15

Chemical synthesis of photo-crosslinking probe P7C3-S326



N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-4-(4-(prop-2-yn-1-yloxy)benzoyl)benzamide (P7C3-S326).

3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropan-1-amine (Naidoo et al., 2014) (40.2 mg, 0.10 mmol) was added to a solution of 4-(4-(prop-2-yn-1-yloxy)benzoyl)benzoic acid (Bandyopadhyay et al., 2011) (28.5 mg, 0.10 mmol), *N*-(3-dimethylaminopropyl)-*N*'-ethylcarbodiimide hydrochloride (21.2 mg, 0.11 mmol) and 1-hydroxybenzotriazole hydrate (15.0 mg, 0.11 mmol) in dimethylformamide (0.4 ml). The reaction went to completion within an hour. The mixture was

25

diluted with EtOAc and washed several times with water and then brine. The organic layer was dried over Na₂SO₄, filtered and condensed to give a light brown solid in 90% yield. ¹H NMR (Acetone-d₆, 400 MHz) δ 8.41 (dd, *J* = 2.0, 0.6 Hz, 2H), 8.07 (d, *J* = 8.4 Hz, 2H), 7.82 (dd, *J* = 10.3, 8.6 Hz, 4H), 7.71 – 7.56 (m, 4H), 7.16 (d, *J* = 8.9 Hz, 2H), 5.39 – 5.10 (dm, 1H), 4.94 (d, *J* = 2.4 Hz, 2H), 4.91 – 4.85 (m, 1H), 4.82 (d, *J* = 5.4 Hz, 1H), 4.05 – 3.89 (m, 1H), 3.87 – 3.70 (m, 1H), 3.17 (t, *J* = 2.4 Hz, 1H). ¹³C NMR (CD₂Cl₂, 100 MHz): 194.6, 167.3, 161.7, 141.4, 140.1, 136.9, 132.8, 130.7, 130.2, 129.7, 127.3, 124.1, 123.6, 114.9, 113.0, 111.2 (*J*_{C-F} = 1.9 Hz), 92.1 (*J*_{C-F} = 176.2 Hz), 78.2, 76.3, 56.4, 45.8 (*J*_{C-F} = 22.5 Hz), 42.3 (*J*_{C-F} = 21.2 Hz). MS (ESI), *m/z*: calculated 660.01, found 660.7 (M+1).

Live-cell crosslinking with photo-crosslinking derivative P7C3-S326

P7C3-S326 was diluted to 0.3 μM in culture medium to treat H2122 cells. After incubation at 37°C for 2 hours, H2122 cells were irradiated for 15 minutes under 306nm ultraviolet light in a Stratalinker 2400 (Stratagene). Cells were then harvested by dissolving in 1% SDS lysis buffer 50mM HEPES, pH 8.0, 2mM MgCl₂, 10mM KCl, 1% SDS, 50 units/ml of Benzonase (Sigma), supplemented with Sigmafast protease inhibitor (Sigma).

Attachment of fluorescent tags via copper-catalyzed azide-alkyne cycloaddition (CUAAC) CLICK reaction

For copper-catalyzed azide-alkyne cycloaddition CLICK reactions, 43 μl of SDS lysate were mixed with 3 μl of 1.7 mM Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA), 2 μl of 50mM CuSO₄, 1 μl of 50mM Tris(2-carboxyethyl)phosphine (TCEP), and 1 μl of 1.25mM Alexa 532-azide. The reaction was incubated at room temperature with constant agitation at 1,000rpm on a thermomixer (Eppendorf) for 1 hour. Samples were then mixed with SDS sample loading buffer and loaded on an 8% SDS-PAGE gel, separated, and imaged using a Typhoon imager (filter settings: excitation 533nm, emission 555nm, and high sensitivity).

In vivo binding competition assay

H2122 cells were incubated with the P7C3-S326 (0.3 μM) in the absence or presence of P7C3 analogs for 2 hours following by UV crosslinking. Cells were lysed in 1% SDS lysis buffer and lysates were

conjugated to the fluorescent Alexa 532 dye using CLICK reaction. The samples were run on SDS-PAGE gels scanned using a Typhoon Imager. The p70 band intensity was analyzed and quantified by Image J, and the relative intensity in each assay was normalized to that of the DMSO control.

5 Two-dimensional gel electrophoresis

H2122 cells were incubated with P7C3-S326 (0.3 μ M) in the absence or presence of 5 μ M of the active analog P7C3-A20 for 2 hours followed by UV crosslinking. Cells were dissolved in 1% SDS lysis buffer and protein concentration was quantified by the BCA assay. For CLICK reactions, 1mg of lysate prepared from P7C3-S326 treated cells were reacted with Alexa 532-azide (Red), and 1mg of
10 lysate from P7C3-S326 and P7C3-A20 treated cells were reacted with Cy5-azide (Green). After the CLICK reaction, the two lysates were combined, mixed with 4 volumes of acetone, incubated at -20°C overnight. Precipitated proteins were collected by centrifugation at 8,000g, 15 min, 4°C. After two washes with acetone, the pellet was air-dried and resuspended in 500 μ l of 2D rehydration buffer (8M urea, 2% CHAPS (wt/vol), 50mM dithiothreitol (DTT), 2% of IPG buffer). For two-
15 dimensional gel electrophoresis, 500 μ g of proteins was loaded onto immobilized pH gradient (IPG) strip of 24cm pH 3-10 linear (GE Healthcare) by passive rehydration using rehydration chamber for overnight at room temperature. Isoelectric focusing was conducted on an IPG Phor3 manifold (GE healthcare) with the following protocol: 100V for 3 hours, 300V for 2 hours, 500V for 3 hours (Step-and-hold); 1000V for 1 hour (Gradient); 8000V for 3 hours (Gradient); 8000V for 4 hours (Step-and-
20 hold) with total 42,000 V/hour. After isoelectric focusing, the strip was equilibrated for 15 minutes in equilibration buffer I (6M urea, 2% SDS (wt/vol), 0.375M Tris; pH 8.8, 20% glycerol (v/v), 100mM DTT) for 15 minutes followed by equilibration buffer II (6M urea, 2% SDS (wt/vol), 0.375M Tris; pH 8.8, 20% glycerol (v/v), 250mM iodoacetamide) for 15 minutes. Proteins were separated in the second dimension on 7.5% SDS-PAGE using Ettan Daltsix unit (GE Healthcare) at a constant current
25 of 40mA/gel for 5-6 hours at 100W. Gel images were scanned at a resolution of 100 μ m with on Typhoon FLA9500 scanner using default settings for CyDyes (GE Healthcare) and preprocessed using Image Quant TL software v8.1 (GE Healthcare). Cropped gel images were analyzed using DeCyder2D Differential Analysis Software v7.1 (GE Healthcare) to detect, normalize and quantify the protein features in the images. The P7C3-A20-competed green spots and several background spots were

identified and robotically excised by an Ettan Spot Picker (GE Healthcare).

Mass spectrometry for protein identification

Gel pieces were washed using 50mM TEAB (triethylammonium bicarbonate, pH 8.0) in 50% (v/v) acetonitrile followed by reduction with 20mM DTT and alkylation with 55mM iodoacetamide, followed by dehydration using 100% (v/v) acetonitrile, air-dried, and then rehydrated in the presence of 250ng of sequencing grade trypsin (Sigma) in 50mM TEAB. Digests were allowed to proceed overnight at 37°C. Mass spectrometry was performed using Q Exactive mass-spectrometers (Thermo Fischer, Bremen), coupled to identical Ultimate 3000 RSLCnano HPLC systems (Dionex, Sunnyvale CA). Peptides were loaded onto a 75µm i.d. x 50 cm Thermo Scientific Easy-Spray column packed with 2µm resin. A 40 minute linear gradient of 1%-28% acetonitrile in 0.1% formic acid followed by a 10 minute ramp to 98% ACN, using a flow rate of at 350nl/min, was employed to elute peptides from the column. The Easy-Spray column was heated to 55°C using the integrated heater. HCD analyses were performed on the Q Exactive instrument using a data-dependent top 20 method, with the full-MS scans acquired at 70K resolution (at m/z 200) and MS/MS scans acquired at 17.5K resolution (at m/z 200). The under-fill ratio was set at 0.1%, with a 3m/z isolation window and fixed first mass of 100m/z for the MS/MS acquisitions. Charge exclusion was applied to exclude unassigned and charge 1 species, and dynamic exclusion was used with duration of 15 seconds.

20 Measurement of intracellular NAD abundance

By LC-MS:

Cellular metabolites were extracted using 50% methanol by multiple freeze-thaw cycles. The cleared metabolites were dried in a Speed-Vac. The dried materials were dissolved in 0.1% formic acid and subjected to mass spectrometric analysis using a specific method developed for NAD. Relative intracellular NAD levels (NAD ion counts divided by total ion counts) were used for inter-sample comparisons.

By NAD/NADH-Glo assay kit:

Assay was performed following the manufacturer's protocol. NAD/NADH-Glo reagent contains the NAD Cycling Enzyme that converts NAD⁺ to NADH. In the presence of NADH, the enzyme reductase

reduces a proluciferin reductase substrate to form luciferin. Cells were grown in 96- or 384-well plates. 50µl or 15µl of NAD/NADH-Glo™ Detection Reagent were added to each well. The resulting luminescence signals were measured by Tecan plate reader or EnVision multimode plate reader (Perkin Elmer).

5

Nicotinamide flux analysis with ¹⁴C-labeled nicotinamide

Logarithmically growing cells cultured in 6-well plates were treated with doxorubicin (0.5 µM) for 48 hours. Afterwards, 1µl of 0.5 µCi/ml ¹⁴C nicotinamide (specific activity: 50 mCi/mmol; American Radiolabeled Chemicals, Inc.) was added per well six hours later. Cells were washed with PBS and collected by trypsin digestion. Metabolites were extracted from cells with 50µl of perchloric acid (0.5 M) by incubating on ice for 20 minutes. The extracts were then neutralized with 13.75µl of KCl/KOH (0.5 M/2.0 M) and centrifuged at 2500 × g for 10 min at 4°C. 10µl of extracted metabolites were separated and identified using silicon thin-layer chromatography plates with 1M ammonium acetate:ethanol (3:7) as solvent. For autoradiography, chromatograms were exposed to storage Phospho screen for 3 days. Afterwards, the screen was scanned using the Typhoon scanner, and the ¹⁴C-labeled compounds were quantified using Image J.

10

15

In vitro NAMPT enzyme assay

NAMPT activity was determined by a coupled-enzyme spectrometric assay as described by Khan *et al.* (Khan *et al.*, 2006) with minor modifications. Briefly, NAMPT first converted nicotinamide to NMN, which was followed by sequential production of NAD via nicotinamide mononucleotide adenylyl-transferase (NMNAT). NAD was then reduced to NADH by alcohol dehydrogenase (Sigma) using alcohol as the substrate. The resulting NADH was monitored by OD340nm. Human NAMPT and NMNAT were over-expressed in *E. coli* and purified as described (Wang *et al.*, 2006) and (Zhou *et al.*, 2002), respectively. The reaction mixture contained 50mM Tris (pH8.0), 0.4mM phosphoribosylpyrophosphate (PRPP, Sigma) 2.5mM ATP, 12mM MgCl₂, 1.5% (v/v) ethanol, 10mM semicarbazide (Sigma), 0.02%(w/v) BSA, 2.4ug/ml NMNAT, 0.4 unit alcohol dehydrogenase, 1uM NAMPT, and 150uM nicotinamide. 10mM stocks of P7C3 analogs in DMSO were further diluted in ethanol prior to applying to the reaction. To minimize variation, a control reaction was run in each

20

25

assay prior to compound addition.

Statistics

Correlation data analysis was performed in GraphPad Prism 6. All p values were obtained using
 5 Spearman Rank Correlation (v1.0.1) in Free Statistics Software (v1.1.23-r7), Office for Research
 Development and Education, URL http://www.wessa.net/rwasp_spearman.wasp/

REFERENCES

- 10 Araki, T., Sasaki, Y., and Milbrandt, J. (2004). Increased nuclear NAD biosynthesis and SIRT1
 activation prevent axonal degeneration. *Science* 305, 1010-1013.
- Bandyopadhyay, S., and Bong, D. (2011). Synthesis of trifunctional phosphatidylserine probes for
 identification of lipid-binding proteins. *Eur. J. Org. Chem.* 2011, 751-758.
- 15 Coleman, M.P., Conforti, L., Buckmaster, E.A., Tarlton, A., Ewing, R.M., Brown, M.C., Lyon, M.F., and
 Perry, V.H. (1998). An 85-kb tandem triplication in the slow Wallerian degeneration (Wlds) mouse.
Proceedings of the National Academy of Sciences of the United States of America 95, 9985-9990.
- 20 Conforti, L., Tarlton, A., Mack, T.G., Mi, W., Buckmaster, E.A., Wagner, D., Perry, V.H., and Coleman,
 M.P. (2000). A Ufd2/D4Cole1e chimeric protein and overexpression of Rbp7 in the slow Wallerian
 degeneration (Wlds) mouse. *Proceedings of the National Academy of Sciences of the United States*
of America 97, 11377-11382.
- 25 De Jesus-Cortes, H., Xu, P., Drawbridge, J., Estill, S.J., Huntington, P., Tran, S., Britt, J., Tesla, R.,
 Morlock, L., Naidoo, J., et al. (2012). Neuroprotective efficacy of aminopropyl carbazoles in a mouse
 model of Parkinson disease. *Proceedings of the National Academy of Sciences of the United States*
of America 109, 17010-17015.
- 30 Gomes, A.P., Price, N.L., Ling, A.J., Moslehi, J.J., Montgomery, M.K., Rajman, L., White, J.P., Teodoro,
 J.S., Wrann, C.D., Hubbard, B.P., et al. (2013). Declining NAD(+) induces a pseudohypoxic state
 disrupting nuclear-mitochondrial communication during aging. *Cell* 155, 1624-1638.
- Kempermann, G., Kuhn, H.G., and Gage, F.H. (1997). More hippocampal neurons in adult mice living
 in an enriched environment. *Nature* 386, 493-495.
- 35 Khan, J.A., Tao, X., and Tong, L. (2006). Molecular basis for the inhibition of human NMPRTase, a
 novel target for anticancer agents. *Nat Struct Mol Biol* 13, 582-588.
- Kim, S.E., Ko, I.G., Kim, B.K., Shin, M.S., Cho, S., Kim, C.J., Kim, S.H., Baek, S.S., Lee, E.K., and Jee, Y.S.
 (2010). Treadmill exercise prevents aging-induced failure of memory through an increase in

neurogenesis and suppression of apoptosis in rat hippocampus. *Exp Gerontol* 45, 357-365.

Kim, W.R., Park, O.H., Choi, S., Choi, S.Y., Park, S.K., Lee, K.J., Rhyu, I.J., Kim, H., Lee, Y.K., Kim, H.T., et al. (2009). The maintenance of specific aspects of neuronal function and behavior is dependent on programmed cell death of adult-generated neurons in the dentate gyrus. *Eur J Neurosci* 29, 1408-1421.

Kolb, H.C., Finn, M.G., and Sharpless, K.B. (2001). Click chemistry: Diverse chemical function from a few good reactions. *Angewandte Chemie International Edition* 40, 2004-2021.

Kuhn, H.G., Biebl, M., Wilhelm, D., Li, M., Friedlander, R.M., and Winkler, J. (2005). Increased generation of granule cells in adult Bcl-2-overexpressing mice: a role for cell death during continued hippocampal neurogenesis. *Eur J Neurosci* 22, 1907-1915.

Lunn, E.R., Perry, V.H., Brown, M.C., Rosen, H., and Gordon, S. (1989). Absence of Wallerian Degeneration does not Hinder Regeneration in Peripheral Nerve. *Eur J Neurosci* 1, 27-33.

Mack, T.G., Reiner, M., Beirowski, B., Mi, W., Emanuelli, M., Wagner, D., Thomson, D., Gillingwater, T., Court, F., Conforti, L., et al. (2001). Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. *Nat Neurosci* 4, 1199-1206.

MacMillan, K.S., Naidoo, J., Liang, J., Melito, L., Morlock, L., Huntington, P.J., Estill, S.J., Longgood, J., Becker, G.L., et al. (2011). Development of proneurogenic, neuroprotective small molecules. *J Am Chem Soc* 133, 1428-1437.

Malberg, J.E., Eisch, A.J., Nestler, E.J., and Duman, R.S. (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. *J Neurosci* 20, 9104-9110.

Munoz-Gamez, J.A., Rodriguez-Vargas, J.M., Quiles-Perez, R., Aguilar-Quesada, R., Martin-Oliva, D., de Murcia, G., Menissier de Murcia, J., Almendros, A., Ruiz de Almodovar, M., and Oliver, F.J. (2009). PARP-1 is involved in autophagy induced by DNA damage. *Autophagy* 5, 61-74.








Naidoo, J., De Jesus-Cortes, H., Huntington, P., Estill, S., Morlock, L.K., Starwalt, R., Mangano, T.J., Williams, N.S., Pieper, A.A., and Ready, J.M. (2014). Discovery of a Neuroprotective Chemical, (S)-N-(3-(3,6-Dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine [(-)-P7C3-S243], with Improved Druglike Properties. *J Med Chem.* 57, 3746-3754.

Pacher, P., Liaudet, L., Bai, P., Virag, L., Mabley, J.G., Hasko, G., and Szabo, C. (2002). Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. *J Pharmacol Exp Ther* 300, 862-867.









Pieper, A.A., McKnight, S.L., and Ready, J.M. (2014). P7C3 and an unbiased approach to drug discovery for neurodegenerative diseases. *Chem Soc Rev.* (in press).









- Pieper, A.A., Xie, S., Capota, E., Estill, S.J., Zhong, J., Long, J.M., Becker, G.L., Huntington, P., Goldman, S.E., Shen, C.H., et al. (2010). Discovery of a proneurogenic, neuroprotective chemical. *Cell* 142, 39-51.
- 5 Preiss, J., and Handler, P. (1958). Biosynthesis of diphosphopyridine nucleotide. I. Identification of intermediates. *Journal of Biological Chemistry* 233, 488-492.
- Stein, L. R. and Imai, S.-I. (2014). Specific ablation of NAMPT in adult neural stem cells recapitulates their functional defects during aging. *EMBO Journal* 33, 937-1085.
- 10 Sun, W., Winseck, A., Vinsant, S., Park, O.H., Kim, H., and Oppenheim, R.W. (2004). Programmed cell death of adult-generated hippocampal neurons is mediated by the proapoptotic gene Bax. *J Neurosci* 24, 11205-11213.
- 15 Tesla, R., Wolf, H.P., Xu, P., Drawbridge, J., Estill, S.J., Huntington, P., McDaniel, L., Knobbe, W., Burket, A., Tran, S., et al. (2012). Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis. *Proceedings of the National Academy of Sciences of the United States of America* 109, 17016-17021.
- 20 Tu, B.P., Mohler, R.E., Liu, J.C., Dombek, K.M., Young, E.T., Synovec, R.E., and McKnight, S.L. (2007). Cyclic changes in metabolic state during the life of a yeast cell. *Proceedings of the National Academy of Sciences of the United States of America* 104, 16886-16891.
- 25 van Praag, H., Kempermann, G., and Gage, F.H. (1999). Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus. *Nat Neurosci* 2, 266-270.
- Wang, J., Alexander, P., Wu, L., Hammer, R., Cleaver, O., and McKnight, S.L. (2009). Dependence of mouse embryonic stem cells on threonine catabolism. *Science* 325, 435-439.
- 30 Wang, T., Zhang, X., Bheda, P., Revollo, J.R., Imai, S., and Wolberger, C. (2006). Structure of Nampt/PBEF/visfatin, a mammalian NAD⁺ biosynthetic enzyme. *Nat Struct Mol Biol* 13, 661-662.
- 35 Zhou, T., Kurnasov, O., Tomchick, D.R., Binns, D.D., Grishin, N.V., Marquez, V.E., Osterman, A.L., and Zhang, H. (2002). Structure of human nicotinamide/nicotinic acid mononucleotide adenylyltransferase. Basis for the dual substrate specificity and activation of the oncolytic agent tiazofurin. *Journal of Biological Chemistry* 277, 13148-13154.









Table 1

compound #		Neurogenesis	Dox:tox protection	Binding competition	NAD recovery	NAMPT activation	notes
		# BrdU+ Cells (X10E06)/mm3 Dentate Gyrus	Δ (Sinf-S0)/AC50		Δ (Sinf-S0)/AC50		
vehicle	DMSO	7.3	0.0	1.0	0.0	0.98	
P7C3		15.0	52.3	2.6	30.6		
S1		10.8	52.2				
S2		8.1	232.0	3.7	109.3		
S3		9.2	20.1	2.3	0.0	1.06	
S4		11.7	0.0	1.4	0.0	1.01	
S5		12.2	-27.8	1.4			
S6		8.4	0.0	1.4	0.0		










S7		15.5	47.7	2.0	29.3		
S8		7.8	141.0	4.7	37.4		
S9		11.9	-20.1	2.0			
S10		19.0	195.8	3.8	265.3	1.37	A20
S11		12.8	68.8	2.0	39.4	1.21	
S12		10.8	55.3	2.4	23.0	1.24	
S13		11.6	151.5	1.7	54.8	1.21	
S14		13.5	202.3	4.5	34.3		
S15		7.6	156.7	5.3	35.6		










S16		9.2	191.9	3.1			
S17		14.9	0.0	1.9	0.0		
S18		10.9	19.9	1.7	0.0		
S19		10.5	53.8	2.9	32.9		
S20		12.7	-19.9	1.3			
S21		8.8	20.4	2.3	31.6		
S22		6.7	0.0	2.7	31.0		
S23		7.4	138.5	2.1	30.9		

S24		8.0	44.8	3.1	51.5		
S25		7.0	30.5	1.4	30.3		
S26		7.5	0.0				A35
S27		8.1	109.9	2.8	38.4		
S28		13.6	31.3	2.8			
S29		9.5	53.8	4.2	60.6		
S30		14.3	22.2	3.3	26.6		
S31		10.4	464.0	6.2	145.1		










S32		13.8	21.4	2.7	0.0		
S33		11.6	80.2	2.8	28.7	1.12	
S34		7.6	0.0	1.0	0.0		
S35		8.6	0.0				
S36		8.9	71.4	3.1	30.8		
S38		13.7	240.7	4.2	31.6		
S39		14.8	129.8	2.6	31.9		
S40		8.1	32.4	2.8	0.0		









S41		15.3	35.5	3.4	0.0		
S42		11.7	50.0	1.7	30.3		
S43		11.7	98.3	1.7	31.5		
S45		8.0	-24.3	1.2			
S46		9.2	-31.8	1.9			
S47		10.1	56.2	5.5	109.2		
S48		14.5	40.2	3.4	28.3		
S49		12.0	171.0				
S50		16.2	74.9	3.8	26.4		









S51		13.2	38.5	2.4	0.0		
S52		10.8	69.9	4.3	28.0		
S53		17.1	105.1	1.4	25.8	1.05	
S54		16.7	1612.9	3.8	0.0		
S55		13.8	92.4				
S56		8.4	21.4	1.0	0.0	1.06	
S57		11.9	161.2				
S58		7.2	454.6	2.5	99.7		
S59		10.7	57.8	1.2	0.0	1.02	










S60		12.6		1.4			
S62		11.8	22.5	1.2	0.0		
S63		8.3	20.0	1.5	0.0		
S64		8.6	94.2				
S65		12.9	42.1	3.3	80.8		
S66		9.7	140.9	3.5	48.9	1.21	
S70	 Molecular Weight: 577.28	7.4	298.9	2.5			
S71		7.2	122.8	3.1	80.0		
S72		11.7	0.0	1.4	0.0		









S73		10.4	22.1	1.2	0.0		
S75		10.3/6.9	0.0	2.5	0.0		
S76		14.2	0.0	1.1	0.0		
S77		12.0	173.0	3.3	40.3		
S78		14.1	151.5	2.7	25.9		
S79		13.7	106.7	1.0	42.9		
S80		13.0	97.4	0.9	35.9		
S81		12.6	66.8	1.2	28.9	0.96	
S82		11.8	71.2	2.3	28.6		









S83		12.5	0.0	1.0	0.0	1.01	
S84		12.8	0.0	1.2	0.0		
S85		8.4/13.0	-39.7	0.9			Clomipramine (tricyclic antidepressant, SNRI and SSRI)
S86		9.7	-27.1	1.3			Amitriptyline (serotonin, norepinephrine reuptake inhibitor)
S87		14.7	-21.7	1.2			Desipramine
S88		7.8	-24.3	1.1			Imipramine
S89		8.7	-38.5	1.3			Nortriptyline
S90		11.1	-39.2	1.4			Protriptyline
S91		8.2	20.0	3.4	31.2		









S92		8.4	20.0	2.5			
S93		11.9	0.0	1.4	0.0		
S94		8.5	0.0	3.8			
S95		8.6	71.2	4.6	30.2		
S96		8.7	55.6	3.9	22.7		
S97		7.6	-31.6	2.0			
S98		6.9	0.0	1.1	0.0		
S99		7.6	0.0	2.5	30.3		










S101		9.9	20.0	2.4	0.0	1.12	
S102		8.9	-35.3				
S103		7.0	24.1	1.9	0.0	0.97	
S104			0.0				
S105		10.8	-32.9	1.2			
S106		10.9	0.0	1.4	0.0		
S107		7.3	160.8	3.5	30.3		
S108		7.6	-77.6	1.0			










S109		9.4	-64.5	1.2			
S110		10.5	325.4	6.2	35.5		
S111		12.3		4.1			
S112				1.2			
S115		6.6/9.6	17.4	3.7	0.0		
S116		11.0	0.0	1.2	0.0		Nardi (MAOI)
S117		8.1	0.0	1.0	0.0		Selegiline (MAOI)
S118		8.3	0.0	1.3	0.0		Parnate (MAOI)
S119		8.6	-18.6	1.2			Celexa (SSRI)










S120		10.4/8.8	-38.1	1.3			Paxil (SSRI)
S121		11.1	-32.9	2.3			CPZ (dopamine antagonist)
S122		10.0	-28.0	1.4			Prozac (SSRI)
S123		9.4	-63.3	1.5			Zoloft (SSRI)
S124		8.9	0.0	1.1	0.0		Effexor (SNRI)
S125			0.0	1.1	0.0		Wellbutrin (NDRI)
S126		8.8	0.0	1.3	0.0		Remeron (tetracyclic, SNRI and SSRI)
S127		6.9	-17.2	1.2			Buspar (dopamine antagonist)










S128			-37.4				
S129			0.0				
S130			-34.0	2.9			
S131		7.3	-34.4	3.5			
S132		11.4	20.0	1.3	29.0		
S133		10.1	0.0	1.2	0.0		
S134		9.7	20.0	1.9	30.3		
S135		7.1	20.0	3.4	0.0		










S136		6.5	513.7	5.7			
S137		12.2	358.9	4.5	130.5		
S138		10.4	209.3	6.5	30.3		
S140		11.7	-18.6	1.2			
S141		11.3	-17.8	2.7			
S143		7.3	0.0	1.3	0.0		
S144		9.1	-41.0	1.4			
S145		12.5	-73.4	2.6			










S146		14.5	78.7	2.8			
S147		13.3	225.1	3.4	37.4		
S148		11.3	-17.4	1.3			tricyclic antidepressant (SNRI and SSRI)
S149		11.6	-17.9	1.2			
S150		8.4	45.8	4.1	30.3		
S152		13.4	-29.7	1.6			
S153		10.7	0.0	1.4	0.0		
S156		15.0	0.0	1.2	0.0		
S157		10.2	-35.9	1.5			










S158		12.5	0.0	1.3	0.0		
S160		13.1	20.0	4.3	0.0		
S161		11.4	24.2	3.1	26.0		
S162		12.6/10.8	0.0	2.3	0.0		
S163		12.1/13.4	164.4	2.5	84.7		
S164		7.6	92.6	1.3	29.2		
S165		17.9/12.4	0.0	1.3	0.0		
S168		14.6	79.7	3.5	30.3		
S169		9.2	39.2	3.0	29.2		









S170		11.2	0.0	1.5	0.0		
S171		13.1	22.1	3.2	0.0		
S172		14.2	-19.4	1.1			
S173		12.8	-18.7	1.0			
S174		9.3	224.2	1.8	0.0		
S176		14.1/6.9	-84.4	4.1			
S177		13.9	-51.0	4.3			
S178		13.8	167.1	1.7	36.2		
S179		17.3	-21.9	0.9			









S180		13.0/9.4	35.7	3.2	31.0		
S181		11.3/8.3	-17.5	0.9			
S182		6.8	-20.1	1.1			
S183		7.7	64.1	4.0	0.0		
S184		6.7	0.0	2.5	0.0		
S185		12.6	0.0	1.5	0.0		
S186		8.1	232.6	3.4	69.1		
S187		12.6	258.9	2.9	101.7		
S188		13.1	173.1	3.1	39.6		










S189		6.9	60.9	3.6	25.5	1.06	
S190		8.4	787.6	4.1	1310.0		
S192		10.5	396.2	4.2	422.6		
S193		7.8	0.0	1.1	0.0		
S194		8.1	1948.4	5.1	0.0		
S195		9.0	20.0	1.1	0.0		
S198		11.0	474.2	5.1	1054.7		
S199		13.3	-49.5	1.1			
S200		11.1	0.0	1.3	0.0		PK11195 (TSPO)

S203		10.8	35.1	3.9	30.3	1.00	
S204		14.2	22.2	2.3	0.0		
S205		14.6	27.9	2.5	46.7		
S206		14.8	0.0	1.4	0.0		
S207		16.2	0.0	1.1	0.0		
S208		13.5	128.3	1.2	111.0	1.16	
S209		15.0	20.0	3.7	0.0		
S210		10.7	0.0	1.1	0.0		
S211		11.5	0.0	1.2	0.0		

S212		10.3	20.0	1.0	0.0	1.04	
S213		6.5	39.7	1.1	27.4	1.00	
S214		9.9	206.5	1.7	41.1		
S215		8.3	220.4	3.6	68.7		
S216		13.0	25.6	4.4	29.9		
S217		12.3	-22.5	2.6		0.89	
S218		9.5	469.6	3.2	126.7		
S219		8.4	-26.9	3.1			
S220		10.5	22.2	2.9	26.3		

S221		14.8	82.8	2.9	56.2		
S222		15.1	0.0	1.3	0.0	1.02	
S223		7.9	23.8	3.0	28.2		
S224		10.1	0.0	1.3	0.0		
S225		15.2	30.9	2.2	30.4		
S226		12.8	49.2	1.9	33.5	0.96	
S227		12.9	0.0	0.9	0.0		
S228		20.2	90.1	2.0	30.3		

S230		15.3	0.0	1.0	0.0	1.02	
S231		13.1	-35.0	1.7			
S232		8.4	0.0	0.9	0.0	1.00	
S233		7.3	0.0	0.9	0.0	0.88	
S234		17.8	20.0	1.0	0.0	0.93	
S235		11.7	24.6	1.8	0.0	0.97	
S236		12.3	0.0	1.7	0.0		
S237		11.8	22.6	1.5	0.0		

S238		9.4	0.0	0.9	0.0		
S239		11.4	0.0	0.9	0.0		
S240		14.3	0.0	1.7	0.0		
S241		15.5	-14.7	1.3			
S242		10.8	0.0	1.2	0.0		
S243		17.9/19.7	184.7	2.2	184.7	1.26	
S244		11.6	-17.2	1.1			
S245		16.2	20.0	1.0	0.0		
S246		14.5		1.3			






S247		15.6	92.6	1.6	0.0		
S248		10.1	0.0	1.3	0.0		
(-)-S243		18.1	402.1	4.8	369.4	1.33	
(+)-S243		10.0	80.4	4.2	92.3	1.13	
S326						1.10	

Table 2

Protein	Description	Length (AA)	mw (Da)	Spot number Indistinguishable Proteins	Spot number			
					1	2	3	4
P43490	NAMPT_HUMAN Nicotinamide phosphoribosyltransferase	491	55630.70		11.96	81.73	37.85	61.77
P11413	G6PD_HUMAN Glucose-6-phosphate 1-dehydrogenase	515	62590.70	P11413-2;P11413-3;	4.98	1.00	2.99	1.00
Q86Y23	HORN_HUMAN Homerin	2850	283074.00		4.00			
F5GWF6	F5GWF6_HUMAN T-complex protein 1 subunit beta	530	52828.60	F8VQ14;P78371;P78371-2;	4.00	1.00	3.00	
P00390	GSHR_HUMAN Glutathione reductase, mitochondrial	522	47363.30	P00390-2;P00390-3;P00390-4;P00390-5;	1.00	2.00	4.00	3.99
C9J8Q5	C9J8Q5_HUMAN Succinate-semialdehyde dehydrogenase, mitochondrial	507	58778.20	P51649;P51649-2;		1.00	4.00	3.00
Q9Y265	RUVB1_HUMAN RuvB-like 1	456	42208.00	Q9Y265-2;	3.98			
K7ENP3	K7ENP3_HUMAN ATP synthase subunit alpha	531	54603.80	P25705;P25705-2;	0.98	0.98	1.97	3.96
P04083	ANXA1_HUMAN Annexin A1	346	38780.00					3.00
B3KV55	B3KV55_HUMAN Glutamate dehydrogenase	391	61521.30	B4DGN5;CONT_DHE3 BOVIN;P00367;			2.98	
P30837	AL1B1_HUMAN Aldehyde dehydrogenase X, mitochondrial	517	57314.30		2.55			0.55
P04279	SEMG1_HUMAN Semenogelin-1	462	52225.90		2.52	1.00	1.52	1.52
B4E3L0	B4E3L0_HUMAN WD40 repeat-containing protein SMU1	352	57651.30	Q2TAY7;		2.00	1.00	2.00
P23246	SFPQ_HUMAN Splicing factor, proline- and glutamine-rich	707	76299.70				0.99	1.99
P14868	SYDC_HUMAN Aspartate-tRNA ligase, cytoplasmic	501	45850.20	Q68CR9;	1.98		0.99	
E7EUE5	E7EUE5_HUMAN Aldehyde dehydrogenase, mitochondrial	470	56489.70	F8VXI5;F8W0A9;P05091;	1.00			
P60709	ACTB_HUMAN Actin, cytoplasmic 1	375	41873.90	P63261;				0.94
A8MVQ3	A8MVQ3_HUMAN Cysteine-tRNA ligase, cytoplasmic	738	94812.00	B4DKY1;P49589;P49589-2;P49589-3;				

CLAIMS

1. A method for identifying a compound having neuroprotective activity, comprising:
incubating a test compound with a nicotinamide phosphoribosyltransferase (NAMPT); and
5 measuring an activity of the NAMPT;
wherein an increase in the activity of the NAMPT compared to a control that is not incubated
with the test compound is indicative of neuroprotective activity of the test compound.
- 10 2. The method of claim 1, wherein in the incubating step, the NAMPT is recombinantly
produced.
3. The method of claim 2, wherein the NAMPT is further purified.
4. The method of claim 1, wherein in the incubating step, the NAMPT is present at about 0.1 to
about 10 μ M, about 0.5 to about 5 μ M, or about 1 μ M.
- 15 5. The method of claim 1, further comprising incubating the test compound with nicotinamide,
phosphoribosylpyrophosphate, alcohol dehydrogenase, nicotinamide mononucleotide
adenylyl-transferase, and an alcohol.
6. The method of claim 5, wherein the alcohol is ethanol.
7. The method of claim 1, wherein the measuring step comprises determining an amount of
nicotinamide adenine dinucleotide reduced form (NADH).
- 20 8. The method of claim 7, wherein the amount of NADH is measured by ultra violet light.
9. The method of claim 8, wherein the amount of NADH is measured by optical density 340 nm.
10. The method of claim 7, wherein an increase in the amount of NADH is indicative of increased
NAMPT activity.
11. The method of claim 1, wherein the test compound having said neuroprotective activity is
25 determined to bind and/or activate the NAMPT.
12. The method of claim 11, further comprising determining that the test compound having said
neuroprotective activity binds and/or activates the NAMPT by mass spec and/or gel
electrophoresis.
13. The method of claim 1, wherein the neuroprotective activity includes one or more of:
30 promoting survival, health, integrity, growth, development and/or function of neurons,

protecting neurons from cell death, apoptosis and/or degeneration, and/or stimulating neurogenesis.

14. A compound having neuroprotective activity, identified by the method of any one of claims 1-13.

5

15. A method for identifying a compound having neuroprotective activity, comprising:
exposing a population of cells to a test compound and a DNA-damaging agent; and
determining survival rate of the population of cells;

10 test compound is indicative of neuroprotective activity of the test compound.
wherein an increase in the survival rate compared to a control that is not treated with the

16. The method of claim 15, wherein the exposing step comprises incubating the population of cells with the test compound and the DNA-damaging agent.

15 17. The method of claim 15, wherein the exposing step comprises incubating the population of cells with the test compound first, followed by the DNA-damaging agent.

18. The method of claim 15, wherein the exposing step comprises incubating the population of cells with the DNA-damaging agent first, followed by the test compound.

19. The method of claim 15, wherein the DNA-damaging agent activates poly-ADP-ribose polymerase (PARP).

20 20. The method of claim 19, wherein the DNA-damaging agent leads to decline in nicotinamide adenine dinucleotide (NAD) level.

21. The method of claim 15, wherein the DNA-damaging agent is an anthracycline.

22. The method of claim 21, wherein the anthracycline is one or more of daunorubicin, doxorubicin, epirubicin, idarubicin, valrubicin and/or mitoxantrone.

25 23. The method of claim 21, wherein the anthracycline is doxorubicin.

24. The method of claim 15, wherein the cells are mammalian cells.

25. The method of claim 15, wherein the test compound is provided at about 1-20 uM, or about 2-10 uM or about 5 uM.

26. The method of claim 15, wherein the test compound is a small molecule.

27. The method of claim 15, wherein the DNA-damaging agent is provided at about 0.01-20 μ M, or about 0.05-10 μ M, or about 0.1-1.5 μ M, or about 0.5 μ M.
28. The method of claim 15, wherein the test compound having said neuroprotective activity is determined to protect the cells from toxicity mediated by the DNA-damaging agent.
- 5 29. The method of claim 15, wherein the test compound having said neuroprotective activity is determined to reduce apoptosis induced by the DNA-damaging agent.
30. The method of claim 15, wherein the test compound having said neuroprotective activity is determined to not protect the cells from toxicity induced by a toxin selected from the group consisting of bortezomib, staurosporine, taxol, brefeldin, cytochalasin D, TNF α and TRAIL.
- 10 31. The method of claim 15, further comprising incubating the test compound with nicotinamide phosphoribosyltransferase (NAMPT) and measuring an activity of the NAMPT, wherein an increase in the activity of the NAMPT additionally confirms the neuroprotective activity of the test compound.
32. The method of claim 31, wherein the test compound having said neuroprotective activity is
15 determined to increase nicotinamide adenine dinucleotide (NAD) level.
33. The method of claim 32, wherein the test compound having said neuroprotective activity is determined to enhance intracellular production of the NAD by increasing the activity of the NAMPT.
34. The method of claim 15, wherein the test compound having said neuroprotective activity is
20 determined to bind and/or activate the NAMPT.
35. The method of claim 34, further comprising determining that the test compound having said neuroprotective activity binds and/or activates the NAMPT by mass spec and/or gel electrophoresis.
36. The method of claim 15, wherein the neuroprotective activity includes one or more of:
25 promoting survival, health, integrity, growth, development and/or function of neurons, protecting neurons from cell death, apoptosis and/or degeneration, and/or stimulating neurogenesis.
37. A compound having neuroprotective activity, identified by the method of any one of claims 15-36.

38. A pharmaceutical composition comprising the compound of claim 14 or 37, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

5 39. A method for the treatment of a disease, disorder, or condition associated with unwanted neuronal cell death, the method comprising administering an effective amount of the compound of claim 14 or 37, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

10 40. A method for the treatment of a disease, disorder, or condition associated with unwanted neuronal cell death, the method comprising administering an effective amount of the compound of claim 14 or 37, or a pharmaceutically acceptable salt thereof, to a patient in need thereof, wherein the compound or salt binds NAMPT.

15 41. A method for the treatment of a disease, disorder, or condition associated with unwanted neuronal cell death, the method comprising administering an effective amount of the compound of claim 14 or 37, or a pharmaceutically acceptable salt thereof, to a patient in need thereof, wherein the compound or salt activates NAMPT.

20 42. The method of any one of claims 39-41, wherein the compound or salt enhances NAD level.

43. The method of any one of claims 39-41, wherein the disease, disorder, or condition is selected from: DNA-damaging agent mediated cardiotoxicity, schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury and/or a visual symptom associated therewith, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, cognitive decline, general frailty associated with normal aging and/or chemotherapy, chemotherapy induced neuropathy, concussive injury, crush

25

30

injury, peripheral neuropathy, diabetic neuropathy, post-traumatic headache, multiple sclerosis, retinal degeneration and dystrophy (such as Leber congenital amaurosis, retinitis pigmentosa, cone-rod dystrophy, microphthalmia, anophthalmia, myopia, and hyperopia), spinal cord injury, traumatic spinal cord injury, peripheral nerve injury (such as peripheral nerve crush injury, neonatal brachial plexus palsy, and traumatic facial nerve palsy), retinal neuronal death related diseases (such as glaucoma and age related macular degeneration, diabetic retinopathy, retinal blood vessel occlusions, retinal medication toxicity (such as what amino glycosides or plaquenil can cause), retinal trauma (e.g., post-surgical), retinal infections, choroidal dystrophies, retinal pigmentary retinopathies, inflammatory and cancer mediated auto immune diseases that result in retinal neuronal cell death), Autism, Stargardt disease, Kearns-Sayre syndrome, Pure neurosensory deafness, Hereditary hearing loss with retinal diseases, Hereditary hearing loss with system atrophies of the nervous system, Progressive spinal muscular atrophy, Progressive bulbar palsy, Primary lateral sclerosis, Hereditary forms of progressive muscular atrophy and spastic paraplegia, Frontotemporal dementia, Dementia with Lewy bodies, Corticobasal degeneration, Progressive supranuclear palsy, Prion disorders causing neurodegeneration, Multiple system atrophy (olivopontocerebellar atrophy), Hereditary spastic paraparesis, Friedreich ataxia, Non-Friedreich ataxia, Spinocerebellar atrophies, Amyloidoses, Metabolic-related (e.g., Diabetes) neurodegenerative disorders, Toxin-related neurodegenerative disorders, Multiple sclerosis, Charcot Marie Tooth, Diabetic neuropathy, Metabolic neuropathies, Endocrine neuropathies, Orthostatic hypotension, Creutzfeldt-Jacob Disease, Primary progressive aphasia, Frontotemporal Lobar Degeneration, Cortical blindness, Shy-Drager Syndrome (Multiple, System Atrophy with Orthostatic Hypotension), Diffuse cerebral cortical atrophy of non-Alzheimer type, Lewy-body dementia, Pick disease (lobar atrophy), Thalamic degeneration, Mesolimbocortical dementia of non-Alzheimer type, Nonhuntingtonian types of chorea and dementia, Cortical-striatal-spinal degeneration, Dementia-Parkinson-amyotrophic lateral sclerosis complex, Cerebrocerebellar degeneration, Cortico-basal ganglionic degeneration, Familial dementia with spastic paraparesis or myoclonus, and Tourette syndrome.

Figure 1





Figure 2



3/35

Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8

8/35





Figure 9



10/35




Figure 10

11/35




Figure 10 cont.




Figure 10 cont.

14/35




Figure 10 cont.

15/35




Figure 10 cont.




Figure 10 cont.

17/35




Figure 10 cont.

18/35

















S144**S145****S146****S147****S148****S149****S150****S152****S153****S156****S157****S158****S160****S161****S162****S163**

Figure 10 cont.

19/35




Figure 10 cont.




Figure 10 cont.

21/35




Figure 10 cont.

22/35




Figure 10 cont.

23/35




Figure 10 cont.





Figure 10 cont.






Figure 12




Figure 12 cont.




Figure 12 cont.




Figure 12 cont.

30/35




Figure 12 cont.

31/35




Figure 12 cont.

32/35




Figure 12 cont.

33/35




Figure 12 cont.

34/35





Figure 12 cont.

35/35



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 14/65058

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - G01N 33/566; C12P 19/36 (2014.01)

CPC - G01N 33/566; C12N9/1077; C12P19/36

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8) - G01N 33/566; C12P 19/36 (2014.01)

CPC - G01N 33/566; C12N9/1077; C12P19/36

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
USPC - 435/7.8; 435/7.92; 435/7.1; 436/501 (keyword limited; terms below)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
PatBase, Google Scholar, Search Terms: neuroprotective, test compound, NAMPT binding, activator, NAD level, increase, DNA damaging, doxorubicin, cell death

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	US 2009/0246803 A1 (IMAI et al.) 01 October 2009 (01.10.2009) entire document, especially paras [0012]; [0015]; [0017]; [0021]; [0052]; [0077]	1-3, 5-13, 14/(1-3,5-13), 15-18, 24- 26, 28-29, 31- 36, 37/(15-18,24-26,28- 29,31-36) ----- 4, 14/4, 19-23, 27, 30, 37/(19-23,27,30)
Y	US 2012/0122924 A1 (CURTIN et al.) 17 May 2012 (17.05.2012) entire document, especially Abstract, paras [0082]; [0882]-[0883]	4, 14/4
Y	US 2012/0022013 A1 (SINCLAIR et al.) 26 January 2012 (26.01.2012) entire document, especially para [0160]	19-20, 37/(19-20)
Y	US 2012/0172584 A1 (SAUVE et al.) 05 July 2012 (05.07.2012) entire document, especially paras [0226]; [0274]	21-23, 27, 30, 37/(21- 23,27,30)

☐ Further documents are listed in the continuation of Box C. ☐

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

28 December 2014 (28.12.2014)

Date of mailing of the international search report

26 JAN 2015

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents

P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 14/65058

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 38-43
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.